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Abstract
The induction of Type I Interferons (IFNs) is a powerful and rapid innate defense mechanism against viral
infection, and many viruses have developed elaborate strategies to overcome the antiviral effects of IFN,
ensuring their survival and replication. Severe acute respiratory syndrome coronavirus (SARS-CoV) is a
highly pathogenic virus that causes severe lung disease in humans and is associated with high mortality
rates. SARS-CoV, like all other successful viruses, encode proteins that counteract the innate immune
response. A number of reports have indicated the papain-like protease (PLpro) domain of SARS-CoV NonStructural Protein 3 (NSP3) as a powerful interferon antagonist, by suppressing interferon regulatory
factor 3 (IRF3) dependent innate antiviral defenses. IRF3 plays a key role in viral-induced type I IFN
induction pathway. Thus, viruses are well-known to evade the establishment of an antiviral state by
regulating the activation of IRF3. However, functional studies detailing the PLpro IFN antagonistic
abilities, are not describe in the context of the full length nsp3 protein, in which it is contained in virus
infected cells. Nsp3 is the largest replicase gene product in the coronavirus genome, which contains
several functional domains that are required for coronavirus replication. Establishment of a stable and
controllable CoV-nsp3 expression system will allow the physiological relevant study of the PLpro
mediated function of this protein. Here, I described the development of tetracycline-inducible mammalian
cell lines for stable expression of the full length nsp3 of HCoV-OC43, HCoV-NL63, MERS-CoV, and SARSCoV, respectively. Although these cell lines exhibited stable and tight control of nsp3 expression in the
presence of tetracycline, I observed a variation in CoV’s nsp3 protein expression levels. However, HeLaFit-SCoV-nsp3 and HeLa-Fit-SCoV-nsp3-delPLP stable cell lines expressed SARS-nsp3 and SARSnsp3-delPLP robustly and at comparable levels. I found that expression of SARS-CoV nsp3 compromised
virus-induced expression of IRF-3-dependent antiviral genes and that such ability depended on the PLpro
domain. In agreement with our previous study examining the effects of the PLpro domain, the inhibitory
effect was downstream of the IRF-3 kinases while upstream of IRF-3. Overall, my data demonstrates that
SARS-CoV nsp3 is a bona fide interferon antagonist, which acts through PLpro-mediated suppression of
IRF-3 activation.
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ABSTRACT
The induction of Type I Interferons (IFNs) is a powerful and rapid innate defense
mechanism against viral infection, and many viruses have developed elaborate strategies
to overcome the antiviral effects of IFN, ensuring their survival and replication. Severe
acute respiratory syndrome coronavirus (SARS-CoV) is a highly pathogenic virus that
causes severe lung disease in humans and is associated with high mortality rates. SARSCoV, like all other successful viruses, encode proteins that counteract the innate immune
response. A number of reports have indicated the papain-like protease (PLpro) domain of
SARS-CoV Non-Structural Protein 3 (NSP3) as a powerful interferon antagonist, by
suppressing interferon regulatory factor 3 (IRF3) dependent innate antiviral defenses.
IRF3 plays a key role in viral-induced type I IFN induction pathway. Thus, viruses are
well-known to evade the establishment of an antiviral state by regulating the activation of
IRF3. However, functional studies detailing the PLpro IFN antagonistic abilities, are not
describe in the context of the full length nsp3 protein, in which it is contained in virus
infected cells. Nsp3 is the largest replicase gene product in the coronavirus genome,
which contains several functional domains that are required for coronavirus replication.
Establishment of a stable and controllable CoV-nsp3 expression system will allow the
physiological relevant study of the PLpro mediated function of this protein. Here, I
described the development of tetracycline-inducible mammalian cell lines for stable
expression of the full length nsp3 of HCoV-OC43, HCoV-NL63, MERS-CoV, and
SARS-CoV, respectively. Although these cell lines exhibited stable and tight control of
nsp3 expression in the presence of tetracycline, I observed a variation in CoV’s nsp3
protein expression levels. However, HeLa-Fit-SCoV-nsp3 and HeLa-Fit-SCoV-nsp3delPLP stable cell lines expressed SARS-nsp3 and SARS-nsp3-delPLP robustly and at
comparable levels. I found that expression of SARS-CoV nsp3 compromised virusinduced expression of IRF-3-dependent antiviral genes and that such ability depended on
the PLpro domain. In agreement with our previous study examining the effects of the
PLpro domain, the inhibitory effect was downstream of the IRF-3 kinases while upstream
of IRF-3. Overall, my data demonstrates that SARS-CoV nsp3 is a bona fide interferon
antagonist, which acts through PLpro-mediated suppression of IRF-3 activation.
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CHAPTER 1.

INTRODUCTION

Brief Overview of Coronaviruses
Coronaviruses (CoVs) are the largest RNA viruses known to date, with nonsegmented positive sense ssRNA genomes of up to 27-32 kb in length (1). CoVs belong
to the family Coronaviridae in the Nidovirales order. The basic genomic organization is
similar for all coronaviruses, an organization that consists of several genes encoding
several nonstructural and structural proteins and a set of accessory proteins that are
unique to each virus species (1, 2). The genomes of several CoVs are illustrated Figure
1.1. All CoVs replicate by a similar and unique mechanism, which is associated with the
synthesis of an extensive 3’-nested set of multiple subgenomic mRNAs for transcription
during infection (1-3). Historically, CoVs were divided into three distinct groups, based
on serological analysis, later confirmed by genome sequencing (1, 4, 5). In 2009, a new
taxonomic nomenclature was adopted, as such CoVs are now divided into genera (alpha-,
beta-, and gammacoronaviruses) corresponding to groups 1, 2, and 3 (6). All mammalian
CoVs, including all bat coronaviruses, SARS-CoV, and MERS-CoV, belong to the first
and second genera, Alphacoronaviruses and Betacoronaviruses, whereas all avian CoVs
belong to the Deltacoronaviruses and Gammacoronaviruses genera. However, within the
Gammacoronavirus genus, there is only one exception, represented by the Beluga whale
coronavirus SW1 strain, which was identified in this aquatic mammal (7). Recently,
three novel CoVs in birds were identified (8). This discovery formed a distinctive genera
of CoVs and now represents a novel genus, Deltacoronavirus (8, 9) Table 1.1.
Coronavirus diversity can be attributed to several factors. First, their large genome size,
coupled with the lack of proof reading in RNA polymerases, leads to a high mutation
rate. Second, with their unique replication mechanism of random template switching,
CoVs have a high recombination frequency, thus promoting their remarkable ability to
jump between species and readily adapt from animal to human hosts (1, 10, 11).
Coronaviruses infect a variety of animal species, including humans, causing
mostly respiratory and enteric pathologies, and in some infrequent cases hepatic and
neurologic pathologies (1,5). Infection can be acute or chronic (1, 5). Many of the animal
coronaviruses, such as infectious bronchitis virus (IBV), porcine epidemic diarrhea virus
(PEDV) and bovine coronavirus (BCoV), are of economic importance and therefore are
very valuable to veterinary research. Human coronaviruses (HCoVs) were first isolated in
the 1960s (1, 12-15). Initially, there were very few studies examining the role of CoVs in
humans, most likely because of their lack of substantiated severe disease-forming
capabilities. HCoVs 229E and OC43 were the first HCoVs to be identified. Since the
late 1960s, they have been recognized as being the causative agent of upper respiratory
tract infections such as the common cold (1, 12-15). However, as an opportunistic
pathogen in more susceptible individuals, including infants, the elderly, and the
immunocompromised, infection can be more severe (16-20).
In late 2002, a previously uncharacterized virus that was associated with the
development of an atypical pneumonia, which often progressed to severe lung disease
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Figure 1.1.

Genomic organization of coronaviruses.

The structures of four coronavirus genomic RNAs are shown. The SARS-CoV genome
and the genomes for human coronavirus Netherlands-63 (HCoV-NL63), mouse hepatitis
virus (MHV) and avian infectious bronchitis virus (IBV) respectively. 5’end consists of a
cap and a leader sequence (L). Red boxes represent ORFs encoding nonstructural
proteins; blue boxes represent ORFs encoding structural proteins; yellow boxes
represents ORFs encoding accessory proteins ORFs; open reading frames. FS: frameshift.
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Table 1.1.

Coronavirus classification.

Genus
Alphacoronavirus

Betacoronavirus

Deltacoronavirus
Gammacoronavirus

Species
Transmissible Gastroenteritis Virus (TGEV)
Porcine Epidemic Diarrhea Coronavirus (PEDV)
Human Coronavirus 229E
Human Coronavirus NL-63
Mouse Hepatitis Virus (MHV)
Human Coronavirus OC43
Human Coronavirus HKU-1
Severe Acute Respiratory Syndrome Coronavirus
(SARS-CoV)
Middle East Respiratory Syndrome Coronavirus
(MERS-CoV)
Bulbul Coronavirus HKU11 (BuCoV-HKU11)
Thrush Coronavirus HKU12 (ThCoV-HKU12)
Munia Coronavirus HKU13 (MuCoV-HKU13)
Infectious Bronchitis Virus (IBV)
Beluga Whale Coronavirus [BWCoV] SW1
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and mortality, was isolated from humans in Guangdong, China (5). The rapid spread of
the disease to over 30 countries in a relatively short period of time represented a major
public health threat. The disease was named severe acute respiratory syndrome (SARS),
and the etiological agent was quickly identified as a highly contagious novel coronavirus
(CoV), designated SARS-CoV (5). The severity of the disease was correlated with
increasing age, with mortality reaching 50% for patients over 60 (6). SARS-CoV is a
betacoronavirus whose genomic sequence, although similar to other betacoronaviruses,
was different enough to make this a member of a new coronavirus subgenera (6). By the
end of the SARS-CoV worldwide epidemic, more than 8000 SARS cases and around 800
deaths due to SARs had been recorded (5). Serological studies suggested that SARSCoV had recently emerged in the human population and that cross-species transmission
from an animal to human host seemed the most plausible reason for its emergence (21).
SARS-CoV caused the first epidemic of the 21st century and is the first paradigm of
serious illness in humans caused by a coronavirus. The fact that a coronavirus could
cause severe disease in humans sparked an interest in the scientific community to
understand SARS-CoV and the new disease.
Subsequently, in 2004 and 2005, two previously unknown HCoVs, NL63 and
HKU1, were discovered and found to cause mild upper respiratory tract infections
worldwide (22, 23). Less than ten years after the SARS epidemic, another novel human
CoV was identified in 2012 to cause clinical pathologies similar to those described in
SARS disease. Many names have been used to refer to this newly identified CoV;
however, due to its origin, it was later named Middle East Respiratory Syndrome
(MERS) CoV (24). In contrast to SARS, MERS progresses to a severe respiratory
infection much more rapidly. MERS-CoV mostly with an origin in the Middle East has
spread to 23 countries in Europe, Asia and the United States of America (25, 26). Similar
to the scenario of the SARS epidemic, it is suggested that MERS-CoV represents another
series of interspecies-transmission events in CoVs (25, 26). To date, the World Health
Organization (WHO) has reported 1621 confirmed cases of MERS-COV infection
globally, resulting in 584 deaths (http://www.who.int/csr/don/4-december-2015-merssaudi-arabia/en/website). Although the number of infected people who are confirmed to
have MERS is less than the number of SARS confirmed cases, the mortality rate resulting
from MERS is a lot higher than the mortality rate resulting from SARS. Nonetheless, the
rather large number of global SARS cases, which spread rapidly in a short amount of
time, highlights the propensity of human CoVs to adapt readily to the human host,
allowing efficient human-to-human transmission. Although there have not been any new
infections reported since 2004, resurgence of SARS or of related viruses from zoonotic
sources remains a distinct possibility, as exemplified by the recent emergence of another
highly pathogenic HCoV, MERS-CoV. Thus far, there are no clinically approved
vaccines or antiviral therapeutics for any of the HCoV infections. Therefore,
understanding how CoVs emerge, infect, and cause disease in the human host is essential.
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Coronaviruses as Emerging Pathogens
All through history, infectious diseases have emerged worldwide and
tremendously affected the well-being of human populations. Many of the emerging
pathogens that impact or threaten human health have emerged from unknown zoonotic
reservoirs, creating a unique challenge to the scientific and medical community. There
have been two known occurrences of emergence of highly pathogenic coronaviruses.
SARS-CoV crossed the species barrier to cause the first pandemic of the 21st century.
Evidence suggests that SARS-CoV emerged from bats to infect palm civets, sold live in
open markets, acting as the intermediate host, facilitating animal-to- human and humanto-human transmission. Examinations of a range of domestic and wild mammals were
conducted in Guandong, China, after the outbreak of SARS, and these examinations
support the hypothesis that marketplace animals may have been the source of the virus
found in humans (27, 28). Animal traders working with live animals in these markets
had high seroprevalence for both the human and animal SARS-CoV, although no prior
history of disease could be detected (27). Furthermore, there is a significant amount of
serological data suggesting that SARS-CoV had not previously been endemic in humans
(21).
Guan et al published evidence establishing that Himalayan palm civets, Chinese
ferret badgers and raccoon dogs all carried SARS-like viruses that were genetically and
antigenically related to human SARS-CoV (27). In particular, it was seen that the viruses
collected from masked palm civets in the early phase of the epidemic and in 2003
exhibited deletions in open reading frame 8 (ORF 8), which differed in length from 29
nucleotides to larger deletions that resulted in the loss of the entire ORF 8 region at the
late phase of the epidemic in 2004, suggesting two separate animal-to-human
transmission events (5, 21, 27, 29, 30). The fact that SARS-CoV was present only in
market or farmed animals, but not in those from the wild (7), suggests that the palm
civets and other marketplace animals are unlikely to have been the natural reservoir hosts
of SARS-CoV, but merely a secondary host bridging the gap between bat SARS-like
CoV and SARS-CoV. The presence of SARS-CoV was detected in different species of
horseshoe bats (31, 32). Sequencing of genomes from bat SARS-like CoVs revealed an
overall nucleotide sequence similarity of 88% to 92% for all bat SARS-like CoVs isolates
to that of the SARS-CoVs isolated from humans or civets (33). The bat viruses also lack
the nucleotide deletion, suggesting that SARS-CoVs and SARS-like CoVs share a
common ancestor (33). These findings indicate that SARS-CoV or SARS-like CoV may
still persist in different unknown animal reservoirs in nature and that a SARS epidemic
may recur in the future.
Bat species have also been implicated as primary reservoirs of MERS-CoV, but
these species are distinct from those that are suggested to have been involved in the
emergence of SARS-CoV (34). Interestingly, in addition to being reported in human
infections, high seropositivity for MERS-CoV has been reported in dromedary camels
(35, 36). Furthermore, viral sequences obtained from these dromedary camels were
almost identical to sequences from two human MERS-CoV cases linked to this farm (37).
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Other animal species such as sheep, goats, and cows were found to be negative for
MERS-CoV neutralizing antibodies (38, 39). Thus, it is very likely that dromedary
camels acquired the virus from bats and that the virus has successively spread between
animals in the Middle East region, a spread representing another zoonotic event occurring
among CoVs to humans. Recently, several reports have demonstrated human-to-human
transmission of MERS-CoV (37, 40). Contrary to the SARS epidemic that was rapidly
controlled, MERS-CoV still spreads more than 3 years after its identification, with its
most recent large outbreak in South Korea (http://www.who.int/csr/don/25-october-2015mers-korea/en/). Also, there is evidence that other human CoVs have emerged from bats,
including HCoV 229E and HCoV NL63 (34, 41-42). These findings and others indicate
that CoVs persist in bats and that these viruses have the ability to mutate, recombine, and
cross species barriers to emerge as novel severe disease-causing pathogens, further
complicating the development of vaccines and antiviral therapeutics.
Currently, there are no-FDA approved vaccines or treatment for SARS or MERS,
so clinical management of patients infected with these highly pathogenic viruses is
mostly dependent on supportive treatment and prevention of complications. Efforts to
develop a vaccine for SARS-CoV have utilized a number of strategies, including
vaccines based on inactivated whole SARS-CoV (1, 43-46), spike subunits (47-49),
recombinant viruses expressing SARS-CoV proteins (50-53), DNA plasmids expressing
SARS-CoV structural proteins (54-55), or virus-like particles (VLPs) (56), which have all
been tested in vitro and in vivo. Although MERS-CoV vaccination approaches are in the
initial stages, Song et al demonstrated a recombinant modified vaccinia virus Ankara
(MVA) expressing the full-length MERS-CoV spike (S) protein (MVA-MERS-S) that
could induce high MERS-CoV neutralizing antibodies in mice (57). Despite the
tremendous efforts given to developing a vaccine for highly pathogenic coronaviruses,
their extensive genetic diversity and high frequency of recombination present challenges
to developing an effective vaccine. For example, vaccination for animal coronavirus IBV
is only partially successful due to the recombination of IBV vaccine viruses and virulent
wild-type strains, resulting in the emergence of antigenic variant viruses that cause
outbreaks of disease in chickens (1, 58). This has been observed in vaccine strains in the
field and in a natural outbreak of IBV (1, 58). Furthermore, enhanced disease was
observed in vaccinated animals that subsequently became naturally infected with feline
infectious peritonitis virus, suggesting that other coronavirus vaccines might also enhance
rather than protect from disease (1).
Since the SARS epidemic, several studies have been conducted to identify potent
antiviral therapeutics for SAR-CoV infection. Attempts have been made to use antiviral
compounds that target specific viral molecules or pathways important to the viral life
cycle. Other attempts have been made to use drugs that enhance the immune response or
provide specific antibodies using passive immunization (1, 59-63). Antiviral drugs that
can control viral loads, thus regulating tissue damage and inflammation, will be most
effective for highly pathogenic coronaviruses. However, at present, there are no specific
antiviral drugs that have been proven effective for any HCoV infection. Within a period
of ten years, two highly pathogenic novel HCoVs, SARS-CoV and MERS-CoV, emerged
from zoonotic reservoirs to cause severe acute respiratory distress syndrome (ARDS) in
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humans and are associated with high mortality rates. Thus, such emergence emphasizes
the need to further understand the virus and host interactions that regulate disease
severity and infection outcome.
SARS Pathogenesis and Acute Respiratory Distress Syndrome
Among the HCoVs known to date, the pathogenesis of SARS appears to be
distinguished by a complex mechanism, which seems to consist of direct and indirect
influences. Specifically, damage to the lung appears to occur directly from SARS-CoV
infection and replication in target cells, as well as a subsequent indirect injury to the lung
mediated by an ill-regulated and aberrant immune response. Prior to the SARS epidemic,
HCoV 229E and OC43 were the only two CoVs known to infect humans (1, 5).
Recognition as pathogens of upper respiratory tract infections, and causing minimum
mortality, made them less interesting, thus generating minimal concern in identifying the
determinants that regulate disease outcomes (1, 12-15). The emergence of SARS
rekindled an interest in CoVs’ molecular and cellular basis of pathogenesis. Furthermore,
it demonstrated that there may be molecular determinants that account for the dramatic
differences in pathogenesis between other HCoVs and SARS-CoV. The most recent
emergence of a novel CoV, MERS CoV, which also causes severe disease in humans,
illustrates the need to understand the pathogenic mechanisms to disease, as well as the
development of therapeutics and vaccines for controlling and preventing CoVs that cause
severe disease in humans.
SARS-CoV infection causes a wide spectrum of disease, varying from “influenzalike” symptoms, such as malaise, fatigue, and high fevers, to a worsening atypical
pneumonia (5, 64-69). In addition, gastrointestinal manifestations and diarrhea were
frequently reported in SARS cases (1, 5, 65-66). Globally, the fatality rate was
approximately 10%, but approached 50% in people 65 years of age or older and those
with underlying illness (WHO update49050703). SARS-CoV-induced mortality is mainly
characterized by progressive respiratory failure, due to a massive inflammatory response
within the lung (ARDS) and a systemic component with widespread extrapulmonary
dissemination, resulting in virus shedding in respiratory secretions, stools, urine, and
possibly even sweat (65, 69-73). Lung-pathology findings in fatal SARS cases were
dominated by diffuse alveolar damage, epithelial cell proliferation, an increase in
macrophages and other severe pulmonary appearances (69, 72, 74-75). Interestingly,
laboratory findings in infected individuals included lymphopenia and neutrophilia (66,
76-78). In contrast to the incubation period of other respiratory pathogens, SARS-CoV
typical incubation period is 4-6 days, yet sometimes as short as 2 days, and peaks at
around day 10 and subsequently declines (1). Transmission of SARS has appeared to
occur primarily by direct person-to-person contact, droplet and airborne routes (5).
Equally important, the virus is shed in the feces and urine, making it plausible that fecaloral transmission can occur (65).
For a virus to cause disease, viral attachment proteins must first bind to specific
receptors and, in some cases, co-receptors on the host cell surface, allowing entry into the

7

cell. Thus, the discovery of virus receptors can provide insight into mechanisms of
pathogenesis. Studies using pseudotyped retroviral and lentiviral vectors, containing the
SARS-CoV spike (S), membrane (M), and envelope (E) proteins independently and in
combination, revealed that the S protein is both indispensable and necessary for virus
attachment to target cells (79-82). SARS-CoV S protein also induces membrane fusion of
the viral envelope with host cell membranes, using a mechanism similar to that of class I
fusion proteins such as human immunodeficiency virus (HIV) gp160, influenza virus
hemagglutinin (HA), and paramyxovirus F protein (83, 84), a process associated with
conformational changes of the S protein. The functional receptor for SARS-CoV has
been shown to be a type I transmembrane metallopeptidase, angiotensin-converting
enzyme 2 (ACE2) (85).
SARS-CoV spike protein plays an essential role in the pathogenesis of SARS.
SARS-CoV is believed to have been transmitted from palm civets to humans during an
interspecies- jumping event. Characterization of human and palm civet receptor usage
revealed that human SARS-CoV can bind both human and palm civet ACE2 whereas the
palm civet virus can only bind to palm civet ACE2. Li et al reported mutations of two
key residues in the receptor-binding domain of the SARS-CoV S protein, responsible for
the adaptation of the virus to human hosts (86). In comparison of the spike protein from
palm civets and humans, molecular analysis of key residues in the receptor-binding
domain showed an accumulation of mutations over a 2-year period, suggesting that
changes in the receptor- binding domain of the S protein can alter host cell specificity and
viral pathogenesis, resulting in pathogenic viruses that cause severe disease in humans
(28, 87).
The major targets of SARS-CoV infection are alveolar Type II pneumocytes and
ciliated cells of the airway epithelium (1, 5, 88, 89). ACE2 is expressed in the lungs,
heart, kidney, and small intestines as well as other tissues (90, 91). Overall, the receptor
expression pattern explains the tissue tropism of SARS-CoV for the lung, small intestine
and the kidney. Still, noteworthy contradictions include the absence of virus in
endothelial cells, where ACE2 is abundantly expressed, compared to the presence of
SARS-CoV in colonic epithelium and hepatocytes that lack ACE2 expression (73, 91).
These inconsistencies suggest that the presence of ACE2 may not be the only
determining factor for tropism of SARS-CoV. The proteolytic enzyme cathespin L seems
to play an important role in the interaction of SARS-CoV and ACE2 expressing cells.
Simmons et al demonstrated that SARS-CoV infection was obstructed by specific
inhibitors of the pH-sensitive endosomal protease cathepsin L (92). In spite of high
expression of ACE2 on endothelial cells, they express low levels of cathespin L,
suggesting that differences in expression of cathespin L in various cell types may explain
these inconsistencies in SARS-CoV infection in relation to ACE2 expression patterns
(91, 92).
DC-SIGN (CD209) and its homolog L-SIGN (also called DC-SIGN-R,CD209L)
are C-type lectins that recognize high mannose-containing carbohydrate residues, present
on viral-enveloped glycoproteins. DC-SIGN is abundantly expressed at the surface of
dendritic cells (DCs) localized in the lymphoid tissues and certain macrophages (93, 94).
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L-SIGN is mostly expressed on endothelial cells in the liver, as well as those in
lymph nodes and the lungs (95). DC-SIGN and L-SIGN function as viral attachment
factors by enhancing viral entry and facilitating infection of cells that express the cognate
entry receptor (in-cis). They are also able to capture viruses and transfer viral infections
to other target cells (in-trans) (96-99). Both have been reported to be additional receptors
for SARS-CoV, yet cells expressing DC-SIGN or L-SIGN in the absence of ACE2 are
not susceptible or are only partly susceptible to SARS-CoV infection, suggesting that
binding to these molecules enhances SARS-CoV infection of ACE2 expressing cells (5,
92, 100, 101). Several reports demonstrate in-trans transmission of SARS-CoV by
dendritic cells to susceptible target cells (79,101). Even though the dendritic cells
examined were capable of transferring infectious virions via a synapse-like structure,
permissiveness for SARS-CoV infection has not been shown (79). A similar mechanism
has been described for HIV, in which HIV-1 travels with its target cells to lymph nodes
where the virus is transferred to T cells at the immunological synapse (99). Viral
exploitation of hijacking these two calcium-dependent lectins subverts the host’s innate
immune defenses and supports virus survival, an observation that may be relevant to
SARS pathogenesis.
The main cause of death in SARS patients is the development of ARDS. ARDS is
the most severe clinical form of acute lung injury (ALI) caused by a mixture of indirect
or direct processes that injure the lung (102). ARDS is best characterized by diffuse
alveolar damage, which is the principle lung pathology observed in fatal SARS cases (69,
74-77,102). Interestingly, in addition to functioning as SARS-CoV receptor, ACE2 plays
an essential role in the renin-angiotensin system (RAS), which may contribute to the
pathogenesis of SARS. The renin-angiotensin system (RAS) plays a central role in the
regulation of cardiovascular and renal functions by maintaining blood-pressure
homeostasis and electrolyte balance (103,104). ACE2 is the only human homologue of
the key regulator of blood-pressure angiotensin-converting enzyme (ACE). ACE is a
metalloproteinase that converts angiotensin I (Ang I) into the potent vasoconstrictor
angiotensin II (Ang II), inducing hypertension while also inducing cell proliferation and
fibrosis (105,106). Contrary to ACE, ACE2 functions as a carboxypeptidase and
negatively regulates the renin-angiotensin system by processing angiotensin I and
angiotensin II (Ang II) into Ang-(1-9) and Ang-(1-7) respectively. Ang-(1-7) is known to
act as a vasodilator, with anti-proliferative and apoptotic functions, as a result,
antagonizing the actions of Ang II (105,106).
Animal experiments using a murine model of ALI demonstrated that ACE2
protects mice from severe acute lung injury induced by acid aspiration or sepsis, which
was facilitated by inactivation of Ang II (107). Furthermore, it was reported that mice
deficient for ACE show significantly improved disease (107). Kuba et al reported that
binding of SARS-CoV S protein to ACE2 considerably reduces the expression of ACE2
in the lung, resulting in a diminished protective role of ACE2 and subsequently acute
respiratory failure (108). In addition, intraperitoneal injection of recombinant SARSCoV S protein intensified ALI in mice, and this effect was ACE2 specific (108). Viral
determinants of SARS-CoV pathogenesis remain to be elucidated. Interestingly, these
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observations provide a possible molecular explanation for the acute respiratory distress
syndrome and lethality associated with severe SARS disease.
SARS-CoV Genomic Organization and Expression Strategy
Coronaviruses’ virions are spherical enveloped particles about 100 to 160 nm in
diameter (1). The association of the large single-stranded positive-sense RNA genome
and the N phosphoprotein forms the long, helical nucleocapsid, inside the virion (1,5, 6).
The virion surface is surrounded by one or two types of projecting spikes. All CoVs
possess the large, petal-shaped spikes, formed by the spike (S) glycoprotein, giving them
their distinctive crown-like morphology, which can be seen under the electron
microscope (1,2,5,6). The S glycoprotein mediates binding to host cell receptors and
membrane fusion whereas the smaller spikes that span the surface of the virion consist of
the hemagglutinin-esterase (HE) glycoproteins and are only present in some
Betacoronaviruses, such as HCoV OC43 and Mouse Hepatitis Virus (MHV)
(1,5,109,110) Figure 1.2. The virion envelope also contains the transmembrane (M)
glycoprotein, a triple-spanning integral membrane protein, which spans the lipid bilayer
three times (1,6,113), and a small envelope (E) protein, which is the least abundant viral
protein present on the virion envelope but has been shown to play a major role in viral
assembly (1,5,6).
The genomic organization of CoVs is very well conserved among all known
coronaviruses. The coronavirus genome is a non-segmented positive-stranded, 5’-capped,
3’-polyadenylated RNA molecule that can function as messenger RNAs (mRNAs) (1).
Encoded within the 5’ end, approximately two thirds of the polycistronic genome is the
replicase gene, which consists of two large, overlapping, open reading frames (ORF) 1a
and 1b that specify the viral nonstructural proteins (nsps). Encoded in the 3’ end,
approximately one third of the genome is the structural proteins arranged in the order
hemagglutinin esterase (HE), if present, spike (S), envelope (E), membrane (M) and
nucleocapsid (N) and internal (I) protein encoded within the N gene for some
CoVs(1,2,5,6). Interspersed between the structural genes is a series of ORFs, encoding
group-specific accessory proteins, which differ among CoVs in number, nucleotide
sequence, and gene order, but are conserved within the same genera (1). Although these
gene products are dispensable for virus replication, it is suggested that these proteins play
a role in virus-host interactions or interfere with the host’s innate immune responses (6,
112-115).
Fourteen functional pen reading frames have been identified in the genome of
SARS-CoV (4, 116). Conserved in all CoVs are homologs of proteins encoded by the
overlapping ORFs 1a and 1b, and by ORFs 2, 4, 5, 6 and 9a (4). Interestingly, neither
SARS-CoV nor MERS-CoV genomic sequence contains a gene for the HE protein,
which is present in most Betacoronaviruses (3, 4, 109, 110, 116-117). Translation of
ORF1a and ORF1ab into two large precursor polyproteins (pp), pp1a and pp1ab, is
dependent on a ribosomal frame-shifting signal encoded near the end of ORF1a
(1,3,4,116,118). The signal regulating the frame-shift consists of a slippery sequence and
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Figure 1.2.

Schematic of coronavirus virion structure.

S, spike glycoprotein; HE, hemagglutinin-esterase glycoprotein; M, membrane
glycoprotein; E, small envelope protein. RNP; RNA-nucleocapsid protein.
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a downstream pseudoknot structure formed by the genomic RNA (5, 119). Encoded
within the polyproteins are two virally encoded cysteine proteases, the papain-like
protease (PLpro) and a 3C-like protease (3CLpro), which in some cases is referred to as
main protease (Mpro). These cysteine proteases are excised by their own proteolytic
activity and are responsible for further processing the pp1a and pp1ab polyproteins
(3,118 120). Processing of the two large polyproteins is necessary for the release and
maturation of 16 nonstructural proteins (nsp1-16) (120).
These nonstructural proteins form a membrane-associated, large multi-subunit
protein replicase complex, which utilizes a reticulovesicular network of double
membrane vesicles (DMV), originating from the rearrangements of the endoplasmic
reticulum (121,122). Along with many unknown cellular factors, this replicase protein
complex is responsible for the replication of the viral genome from a full-length negativestranded template, and the transcription of a nested set of eight subgenomic (sg) mRNAs,
used for translation of structural and accessory proteins (3,4). It has been suggested that
the establishment of DMVs is initiated by the recruitment of replicase proteins to host
membranes, a process facilitated by several transmembrane domain-containing replicase
products, such as nsp3, nsp4 and nsp6 (122-125). This has also been seen with
arteriviruses, another family within Nidovirales order (126, 127). This viral replication
strategy may provide a shielded environment for the protection of viral double-stranded
RNA intermediates from the host cell’s innate immune-detection sensors.
SARS-CoV Multi-Domain Non-Structural Protein 3 (NSP3)
Among the 16 nsps encoded within SARS-CoV replicase polyprotein, special
attention has been given to nsp3, since it is becoming apparent that protein domains
within nsp3 may serve roles in pathogenesis that are distinctive from viral replication.
The SARS-CoV nsp3 protein is the largest nsp in the genome, with 1922 amino acids,
containing several structural and functional domains (3, 4). Nsp3 of SARS-CoV has been
well characterized structurally by either X-ray crystallography or NMR. It has been
estimated that SARS-CoV nsp3 has about 14 domains: UB1, AC, ADRP, SUD-N, SUDM, SUD-C, UB2, PL2pro, NAB, G2M, TM1, ZF, TM2, and Y, which may have 3
structural domains (128). NMR studies were used to determine the structure of the
highly conserved N-terminal region of nsp3, exhibiting an ubiquitin-like 1 (UBL1)
globular fold, followed by an acidic domain (AC domain) rich in glutamic acid (129).
The UBL1 domain is structurally similar to Ras-binding proteins and interferonstimulated gene 15 (ISG15) (128). Although the functional significance of the UBL1
domain has yet to be experimentally validated, these structural similarities may suggest
that this domain may be important for regulating the host cell responses, thus promoting
survival. Following this is the ADP-ribose-1”-phosphatase (ADRP) domain, also called
the X domain or macro domain, thought to play a role during SARS life cycle (130). The
SARS Unique Domain (SUD) follows next and has been considered a domain unique to
SARS-CoV (4). It has been shown that the SUD domain is made up of three domains,
named by their location the N-terminal SUD-N, the middle SUD-M and the C-terminal
SUD-C (131).
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Recently a new domain was identified in MHV nsp3. Interestingly, the authors
show that this novel domain has close structural homology to the SARS-CoV unique
domain C (SUD-C), suggesting that the SUD domain may not be unique to only SARSCoV (132).
Following the SUD domain are an additional UBL domain (UBL2) and the
catalytically active PLpro. Unlike other CoVs that encode two different PLPs, SARSCoV encodes only one PLP domain termed PLpro within nsp3, which is essential for
processing the amino terminal end of the replicase polyprotein at 3 junctions, through the
recognition of LXGG motif, releasing nsp1-nsp3 mature proteins respectively (133). It is
well known that when two PLP domains are encoded within the coronavirus replicase
polyprotein, the PLP2 recognizes the LXGG motif and has similar characteristics to
SARS-CoV PLpro (134). Several studies have revealed that SARS-CoV PLpro is a
deubiquitinating (DUB) enzyme and has de-ISGylating activity (134-139). The host cell
uses both ubiquitin (Ub) and ISG15 as unique signaling components to promote the
antiviral innate immune responses during SARS-CoV infection. The fact that the PLpro
can cleave and disrupt important host cell innate immune elements illustrates the
multifunctional nature of this protease and suggests that it is an excellent drug target for
the development of antiviral treatments. Downstream of the PLpro domain are a nucleic
acid-binding domain (NAB), which may function with RNA chaperone activity, and one
unfamiliar domain named the marker domain (G2M)(125). Subsequent to the G2M
domain are two transmembrane domains, a putative metal- binding region (ZN) and the Y
domain, whose function is unclear (3, 4,125).
Due to the large size of the nsp3 protein, in vitro studies examining the functional
role of domains contained in nsp3 during SARS-CoV infection have predominantly made
use of truncated domain constructs. Specifically, it is unclear whether the protein
domains within nsp3 impact the innate immune responses when expressed in the context
of the full-length nsp3 protein, which is the case in virus-infected cells. Therefore, an
enhanced understanding of viral components that are critical for efficient replication and
negative regulation of the host innate immune responses, ultimately regulating
pathogenesis and virulence, is essential to understanding SARS pathogenesis.
The Effect of Virus Infection on Host Innate Immunity
Virus infection represents an evolutionary arms race between virus and the host.
This antagonistic relationship leads to the host utilizing its intrinsic defense mechanisms
in an attempt to restrict and eliminate virus infection. Viruses, in turn, have adapted
multiple strategies to subvert or even manipulate the host defenses to promote its own
infection. The host innate immune system is the first line of defense against invading
pathogens, including viruses. Hosts have to sense viral pathogens and induce immune
responses for protection. Upon the detection of invading viruses, host cells mount an
immediate antiviral response. While viral recognition triggers early antiviral immune
defenses promoting virus elimination, a consequence of this strong, immediate, innate
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immune response may be an aberrant inflammatory response that could cause severe
disease in the host. Understanding virus and host interactions is critical to the prevention
and treatment of viral diseases.
The host innate immune system is equipped with cellular pattern-recognition
receptors (PRRs) that recognize conserved viral structural components that are
recognized as foreign to the host, called pathogen-associated molecular patterns (PAMPs)
(140). Toll- like receptors (TLRs) were the first PRRs to be identified and remain the best
studied. TLRs are expressed in many cell types including immune cells, such as
macrophages and dendritic cells, and are localized on the cell surface or endosomal
compartments (141, 142). There are 5 TLRs that are key in the detection and control of
viral infection. TLR3 recognizes dsRNA, a replication intermediate generated during the
life cycle of many RNA viruses. TLR2 and TLR4 sense viral structural proteins or
glycoproteins, TLR7 and TLR8 recognize viral ssRNA, and TLR9 senses non-methylated
viral CpG containing DNA (140-142). Thus, viral attachment to the host cell is sensed by
external TLRs, while viral invasion is recognized by TLRs localized internally. Although
no TLR has been directly implicated in the recognition of SARS-CoV, a protective role
for TLRs adaptor proteins was established in MA15-SARS-CoV infection. Wild-type
mice infected with MA15-SARS-CoV exhibited transient weight loss, from which they
recovered after 7 days; however, MyD88-deficient mice lost significantly more weight,
all of which died by day 6 post infection (143). Most recently, Totura et al demonstrated
that mice deficient in the TLR3/TLR4 adaptor TRIF are highly susceptible to SARS-CoV
infection, observing a lung pathology that was similar to those seen in human patients
with severe SARS disease (144). The TRIF-deficient mice also exhibited increases in
weight loss, mortality, and higher viral titers (144). Additionally, TLR4 was identified as
a protective host factor against Betacoronavirus Mouse Hepatitis Virus-1 (MHV-1) in a
respiratory model of SARS disease (145). These findings highlight the significance of
TLR3/TLR4 adaptor proteins in mediating a protective antiviral innate immune response
to highly pathogenic coronavirus infections. TLRs recognize a broad range of PAMPs;
however, it is noteworthy to mention that PRRs other than TLRs are involved in PAMP
recognition and in the regulation of the innate immune response.
Retinoic-acid-inducible gene I (RIG-I)-like receptors (RLRs), such as RIG-I and
MDA5, are also an important class of PRRs that have been shown to recognize conserved
viral-specific components (146). These PRRs are ubiquitously expressed and are
localized in the cytosol where they survey the cytoplasm for viral dsRNA (147).
Although RIG-I and MDA5 both recognize viral RNA, they play differential roles in the
viruses they sense. The difference in the recognition of RNA viruses by RIG-I and
MDA5 has been credited to their distinctive preferences for viral RNA ligands. For RIGI, 5′-triphosphate (ppp)-containing RNAs at least 20 base pairs in length—as well as
short, blunt-ended dsRNAs—have been shown to be the most favorable RIG-I agonist
(148,149). Although MDA5 ligands are less defined, it has been established that their role
is more dependent on long and branched-structure dsRNAs (150). Overall, RLR and TLR
pathways are not redundant, but rather allow the host to combat the virus infection more
efficiently by sensing viruses through multiple pathways by multiple mechanisms in
different cell types.
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In vitro studies indicate that RIG-I and MDA5 are transcribed during SARS-CoV
infection; however, it is not known whether SARS-CoV is recognized by these PPRs
(151). On the contrary, MHV has been shown to be recognized by MDA5 and RIG-I in a
cell-specific manner (152,153). Considering that MHV and SARS-CoV replicate in the
cytoplasm where they produce large amounts of dsRNA, it is likely that SARS-CoV
could be detected by the same sensors. TLRs and RLRs recognize viral PAMPs during
virus infection to activate the host intracellular defense signaling cascades, resulting in
the production of Type I Interferons, inflammatory cytokines and chemokines, and the
subsequent activation of adaptive immunity (146).
One of the most efficient and fundamental events in the induction of the earlyphase antiviral innate immune response is the production of Type I Interferons, named for
their ability to interfere with viral replication (154). There are two essential events of the
Type I IFN system: first, the synthesis of Type I IFNs; second, the response to secreted
Type I IFN’s, Type I IFN-mediated signaling. Type I IFNs can be classified into two
principal classes: IFN-β, the immediate early genes expressed by the initial response to
invading viruses, and IFN-α, the delayed set of genes expressed by a secondary de novo
protein-synthesis pathway (155). At the molecular level, the induction of type I IFNs is
initiated by sensing the invading viral pathogen through the appropriate PRR(s), which
triggers multiple and distinct intracellular signal transduction. Although the pathways
may differ initially, they all converge to activate the latent transcription factors such as
nuclear factor-kappa B and the interferon regulatory factors (IRFs).
The IRF transcription factors are key regulators in the synthesis of type I IFNs. In
particular, IRF-3 and IRF-7 are vital. IRF-3 is constitutively expressed in most cell types
and plays a central role in the production of IFN-β (156). In the absence of virus
infection, this transcriptional factor resides in the cytosol in an inactive state. Upon virus
infection, IRF-3 undergoes serine phosphorylation in its C-terminal region by kinases
of IRF-3, either
a homodimer or a heterodimer with IRF-7, then translocates to the nucleus, where it
recruits the transcriptional co-activators CBP and p300, and binds to its target IFN-β
promoter along with other transcriptional factors to initiate IFN-β mRNA synthesis (156).
This initial wave of IFN triggers expression of a highly homologous IRF, IRF-7. IRF-7
is expressed constitutively at low levels mainly in immune cells. However, it can be
strongly induced by type I IFN-mediated signaling, making it an important element in the
IFN-α/β positive feedback loop, where IFN-α/β enhances its own expression (159). This
phenomenon occurs in a two-step process where IRF-3 induces the early expression of
IFN-β and IFN-α. These genes subsequently signal through the IFN-α/β receptor and the
JAK-STAT pathway to induce IRF-7 expression, which contributes to the amplification
of the transcriptional response through a second wave of interferon gene expression,
which includes other IFN-α genes that are not induced by the initial stage of virus
infection (159). Similar to IRF-3, IRF-7 is located in the cytosol in an inactive form.
Upon virus infection, kinases TBK1 and IKK phosphorylate IRF-7 on its serines in its
C-terminal region, allowing dimerization (157, 158). The dimeric form of IRF-7, either a
homodimer or heterodimer with IRF-3, induces Type I IFN gene expression (159).
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Once transcribed and translated, secreted IFN-β and IFN-α bind to a cell surface
heterodimeric receptor complex consisting of alpha/beta interferon receptor (IFNAR) 1
and IFNAR2 subunits. IFN-β and IFN-α act in an autocrine/paracrine fashion, and bind
to its cognate receptor on the surface of the same cell or neighboring cells to induce IFNβ and IFN-α gene expression and subsequently activate the JAK-STAT pathways (160).
The signal transducers and activators of transcription 1 (STAT1) and STAT2 proteins are
transcriptional factors that reside in the cytosol in a latent form, which become
phosphorylated by members of the Janus kinase (JAK) family, JAK-1 and TYK-2 (160).
Phosphorylated STAT1 and STAT2 form heterodimers that recruit IRF9 to form the
interferon-stimulated gene factor 3 (ISGF3) complex. This heterotrimer complex is
translocated into the nucleus where it binds to IFN-stimulated response element (ISRE) to
induce expression of a large number of IFN-stimulated genes (ISGs), resulting in the
establishment of an antiviral state. IRF-3 and IRF-7 are well known as master regulators
of Type I IFN responses and are firmly integrated within the TLR/RLR dependent
pathways of the innate immune response to invading viral pathogens. Since IRF-3 plays
an essential role in the early induction of antiviral gene expression, many viruses have
developed various mechanisms to inhibit, either directly or indirectly, the activation of
IRF-3, thus blocking or limiting IFN production (156,160). It is well known that the
initial virus-host interactions may significantly impact the course and/or outcome of the
infection. Therefore, understanding the mechanisms by which viruses regulate the early
host innate immune responses is critical to the treatment and prevention of emerging
infectious diseases, such as SARS and MERS.
With respect to the role of the innate immune system in SARS-CoV infection, the
fact that SARS-CoV replicates increasingly in the respiratory tract during the first ten
days of the disease raises the assumption that SARS infection may cause deficiencies in
the host innate immune response (5). The relationship between SARS-CoV and the IFNα/β response is puzzling. Interestingly, in-vitro studies of SARS-CoV, contrary to other
viruses, typically demonstrate that SARS-CoV is a poor inducer of type I IFN (161, 162).
Furthermore, irregular IFN, Interferon Stimulated Genes (ISGs), and cytokine responses
were observed in SARS patients compared to healthy individuals, providing evidence that
SARS may be an innate immune-regulated disease (161,163).
Induction of the Antiviral State by Interferon
In mammals the interferon system is essential for survival because it provides an
early line of defense against viral infection. This system is designed to inhibit viral
replication and block the spread of virus infection in the host. In addition to their
antiviral activities, IFNs also have antiproliferative, antitumor, and immunomodulatory
activities, all of which have a profound effect on the physiology of the cell (154,164).
There are three main IFN families: Type I (IFNα/β) and III (IFNλ) IFNs, which are most
recognized for their antiviral activities, and type II (IFNγ) IFNs, which has antiviral
activities but is best known for its immunomodulatory effects (164). The production of
IFNs is regulated by a highly complex and coordinated sequence of signaling events
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facilitated by PRRs, adaptor proteins, kinases, and transcription factors (165,166). IFNs
are synthesized in host cells in response to viral infection, secreted into circulation, bind
to their cognate receptors, and activate the JAK/STAT pathway to enhance the expression
of hundreds of different ISGs, leading to the establishment of the antiviral state (165,
166).
ISGs are a diverse group of more than 300 genes that mediate the biological
effects of IFNs (1, 164). In addition to their roles as downstream effectors of IFN, a
subset of ISGs is induced in parallel with IFN by dsRNA, and this subset is thought to
mediate the primary response to virus infection (1, 154). Different ISGs inhibit different
steps of viral life cycles, such as viral entry, un-coating, transcription, translation,
assembly and egress (165, 166). This distinctive strategy allows the IFN system to
coordinate a multifaceted attack on virus replication. Studies of ISGs products’ mode of
action have led to important findings concerning translational control, RNA stability and
editing, and protein transport and turnover (1, 164). Among the several hundreds of ISGs
transcriptionally regulated by IFN, only a few have been extensively characterized. These
genes encode the dsRNA-activated protein kinase (PKR), the 2’,5’-oligoadenylate
synthesases (2′–5′ OAS), ribonuclease L (RNase L), the mxyovirus (Mx), and ISG56.
The functions of these proteins are known to be essential for the induction of an antiviral
state by IFN.
PKR is constitutively expressed at low levels but not functional until activated
(167). PKR is activated by the binding of viral dsRNA generated in virus-infected cells as
by-products of viral replication or transcription. Binding of dsRNA to the N-terminal
dsRNA binding motifs (dsRBM) of PKR relieves steric inhibition of the kinase domain;
PKR dimerizes, autophosphorylates and becomes activated (168). Phosphorylated PKR
can phosphorylate other proteins, but not other inactive PKR molecules (169). Therefore,
autocatalytic activation of PKR is prevented. In addition to activation by viral RNAs,
RNAs of cellular and synthetic origin such as IFNγ mRNA and poly I:C can activate
PKR. It has been demonstrated that PKR binds to a pseudoknot structure, with sufficient
double-stranded character, in IFNγ gene’s 5’ untranslated region (UTR), which
subsequently activates PKR to then inhibit translation of the transcript via
phosphorylation of eukaryotic translation-initiation factor 2α (eIF-2α) (168).
Furthermore, two additional ligands, heparin and the PKR activator (PACT)—which is
the only known protein activator of PKR—have been described to directly activate the
kinase (1,154, 170).
Active PKR mediates translational control by phosphorylating the eIF-2α,
resulting in global inhibition of protein synthesis that blocks further viral gene translation
and full amplification of the viral-induced cellular stress response (1, 164). Therefore,
activation of PKR causes inhibition of cellular protein synthesis and apoptosis, which is
one unique strategy for IFN-induced inhibition of viral replication and spread. Besides its
role as a regulator of protein translation, PKR also plays a role in cellular signaling. In
response to stimuli such as poly I:C and TNFα, PKR regulates the activation of NF-ĸB
through the phosphorylation and degradation of IĸBα (1). In addition, PKR has been
suggested as a serine kinase for STAT1, a modification that is required for IFN signaling
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(1). The biological significance of PKR is further observed by the existence of cellular
and viral regulators of PKR action. Because PKR promotes cellular apoptosis, viruses
encode or induce antiapoptotic proteins such as P58IPK, a cellular protein recruited by
influenza virus, to keep cells alive during virus replication (1).
The IFN-inducible 2′–5′ OASs are a family of proteins of different molecular
weights encoded by multiple genes (154). Viral dsRNA can directly activate the OAS
proteins. Activation of OAS does not involve a known RNA binding domain; however, it
has been shown that the RNA binding site consists of a groove of positively charged
amino acids formed from noncontiguous regions of OAS (171). Activated OAS uses ATP
to synthesize 2’,5’-linked oligomers of adenosine (2’-5’A) molecules, yielding mainly a
series of short 5′-triphosphorylated triadenylate called 2-5A [ppp5′(A2′p5′)2A] (172173). The 2′–5′A system also plays a role in antiproliferative activities such as induction
of apoptosis, senescence, and differentiation, suggesting that OAS is also activated by
cellular RNAs in the absence of viral infection (174-176).
The best characterized function of 2′–5′A is activation of the endoribonuclease
RNase L. The 2’–5’A molecules bind to the inactive monomers of RNase L, triggering its
dimerization through their kinase-like domains and activation (177). RNase L functions
to cleave viral ssRNA with specificity for sites 3′ of UpUp and UpAp sequences, and thus
leads to degradation of viral RNAs (164). On the other hand, activated RNase L also
degrades both cellular mRNA and rRNA in the cytoplasm of the cell, leading to damages
of the host cell machinery, which is required for viral replication and can result in
apoptosis. This likely contributes to the antiviral actions of RNase L. Moreover, RNase
L also cleaves self mRNAs and produces small RNAs that function to activate the RLRs
to induce IFN-β, thus perpetuating and amplifying IFN-β production in virus-infected
cells (164).
The IFN-inducible antiviral protein MX is a key mediator of innate antiviral
defenses induced in host cells. The MX potent action in early antiviral host defenses was
identified by studies in genetically defined mouse strains resistant to influenza A viruses.
These studies revealed that resistance was caused by a single gene, Mx1, localized on
chromosome 16 (172,178). Subsequently, two human Mx genes were identified and
shown to encode for proteins called MxA and MxB, respectively (178). Mx proteins are
large GTPases in the dynamin superfamily, which self-assemble into horseshoe- and ringshaped helices and bind to viral nucleocapids (178,179). They inhibit viruses by
interfering with intracellular trafficking and activity of viral polymerases, thus blocking
an early stage of the replication cycle (164). The subcellular location of Mx proteins to
some extent appears to contribute to their antiviral effects on a particular virus. These
proteins can be located in the cytoplasm or in the nucleus. Nuclear Mx proteins have
been shown to confer resistance to viruses, such as Influenza A and Thogoto virus, which
are known to replicate in the host cell nucleus (164,178). Cytoplasmic murine Mx
proteins inhibit the replication of viruses that replicate in the cytoplasm, such as VSV and
LaCrosse virus (LACV) (178). In contrast, some human cytoplasmic Mx proteins have a
wide-range antiviral specificity against different types of viruses, regardless of their
intracellular replication site. These MxA-sensitive viruses include members of the
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bunyaviruses, orthomyxoviruses, paramyxoviruses, rhabdoviruses, togaviruses,
picornaviruses, reoviruses and hepatitis B virus, a DNA virus with a genomic RNA
intermediate (178).
ISG56, which encodes for P56, is one of the first interferon (IFN)-inducible genes
to be discovered and is the most potently induced gene among all ISGs (154). ISG56
belongs to the IFIT genes, which are grouped on human chromosome 10 and consist of 4
members including ISG56, ISG54, ISG60 and ISG58. (180, 181). Normally most cell
types express very low constitutive levels of ISG56 in the absence of stimuli. However,
induction of ISG56 is initiated by many stimuli, such as IFN, dsRNA and many viruses.
Since ISG56 mRNAs are very abundant in virus-infected cells, they are used extensively
as read-outs for studying transcriptional regulation of ISGs by IFN, PRRs, and other
signaling molecules such as IRF-3 (180). The most potent inducer of ISG56 is type I
IFNs (IFNα/β) and type III IFNs (IFNλs), whereas type II IFN (IFN-γ) is a much weaker
inducer. Although novel insights into the functions of the IFIT-encoded proteins
continuously emerge in the literature, the best described function of ISG56 and ISG54 is
the inhibition of cellular translation by binding to specific subunits of eukaryotic
initiation factor 3 (eIF3), presenting a mechanism of cell growth inhibition distinct from
other ISGs such as PKR and OAS (180, 181). Use of this distinct strategy may possibly
delay or inhibit virus replication by diminishing the overall cellular metabolism.
Interestingly, a newly identified function of ISG56 protein product p56 has been reported.
Direct binding of p56 to Human Papillomavirus (HPV) E1 helicase inhibits E1 helicase
activity and sequesters the majority of HPV E1 in the cytoplasm, separating it from the
viral genomes in the nucleus, thus inhibiting viral DNA replication (181-183).
Lastly, many IFN-pathway signaling proteins, such as RIG-I and MDA5, are
themselves ISGs, thus providing an autocrine loop that augments IFN responses. Similar
to RLRs, PKR and OAS proteins are classified as PRRs for the viral PAMP, doublestranded RNA (dsRNA). However, they differ from typical PRRs in that ligand binding
results in direct activation of their enzymatic activity rather than initiation of a signaling
cascade (142, 146,184). Therefore, PKR and OAS can function as early sensors to viral
infection and can also be augmented as a secondary effect of IFN induction through
TLR/RLR pathways. The importance of ISGs is further proven by the finding that several
virally encoded antagonists can specifically interrupt the functions of ISGs products, thus
blocking the establishment of the antiviral state.
IFNs provide a powerful immediate cellular defense against viral infection and
thus are fundamental for mammals’ survival. The IFN system is key to the inhibition of
viral replication and viral spread, which is mediated through the action of specific ISGs.
The restriction of virus replication by several of these IFN-induced proteins is associated
with a multitude of physiological changes for the host cell. Although some ISGs function
to confer a total disruption in the cellular translational machinery to maximize the host
control of virus infection, IFNs also induce counteractive signals that limit the duration or
toxicity of IFN-mediated responses to the host, in an attempt to prevent deleterious
effects and facilitate cell survival in uninfected cells. Most importantly, these responses
constitute a negative feedback loop to counteract the massive reorganization of cellular
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metabolism and machinery triggered by IFN. Furthermore, it is important to consider that
many IFN-induced antiviral proteins in virus-infected cells are directly induced
independent of IFN (1). This consideration suggests that these powerful coordinated
protein functions all work in concert to achieve a fully functional antiviral state and to
maintain host-virus homeostasis, thus exemplifying the importance of the host innate
immune system during viral infection.
Overview of IFN Antagonists
In order to successfully replicate and spread in a host, a virus must circumvent
multiple cellular intracellular signaling pathways regulating a wide variety of host cell
functions. The production of IFNs is an essential mechanism of the host response to viral
infections. However, a main priority for most invading viral pathogens is the downregulation of the IFN system, a powerful first-line host defense against virus infection.
The strategies that viruses use to counteract the IFN system are plentiful and include the
inhibition of IFN synthesis, the inhibition of IFN-mediated signaling pathways, and the
disruption of the action of IFN-induced proteins with antiviral activity (160). Several
different viruses contain an ever growing number of IFN-antagonistic proteins that target
almost all components of the IFN system. These IFN antagonists are typically
multifunctional proteins that are involved in regulating several different functions in
virus-infected cells. For example, the P proteins of some negative-strand RNA viruses
like rabies virus are essential components of the viral RNA polymerase but also inhibit
the induction of IFN-β in virus-infected cells by targeting TBK1, thus disrupting the
activation of IRF-3 (185).
It is well known that CoVs possess multiple mechanisms by which they evade the
host innate immune response, and it has been suggested that this immune evasion may
contribute to severe coronavirus disease, such as SARS (113,114,186,187). The
observation that SARS-CoV induces low, sometimes undetectable Type I IFNs following
productive infection in cell culture, and is relatively resistant to the antiviral effects of
IFN signaling, suggests that the genome may encode antagonists of IFN synthesis and
signaling (162,188). Described below are a few examples of SARS-CoV proteins that
directly affect either IFN induction or signaling.
SARS-CoV encodes the largest number of accessory proteins that share no
homology with accessory proteins from any other HCoV. Although none are essential for
virus replication in cell culture (189), SARS-CoV ORF3b and ORF6 were shown to
block IFN induction and IFN signaling (114). How ORF3b antagonizes
IFN induction has not been well-defined; however, the mechanism by which ORF6
antagonizes the IFN signaling arm of innate immunity has been illustrated. ORF6 protein
disrupts the formation of the nuclear import complex by tethering karyopherin alpha 2
and karyopherin beta 1 to the membrane. The subsequent retaining of nuclear import
factors at the membrane leads to a loss of STAT1 transfer into the nucleus in response to
interferon signaling, thus inhibiting the expression of genes dependent on STAT-1
activation to establish an antiviral state (113). Furthermore, it has been shown that

20

MERS-CoV is more sensitive to PEG-IFN treatment than SARS-CoV is (190). This
profound phenotype may be attributed to the lack of a SARS-CoV ORF6 homologue.
The Nucleocapsid (N) protein of SARS-CoV, a structural component of the
SARS-CoV virion, has been shown to also act as an antagonist of IFN. KopeckyBromberg et al demonstrated that SARS-CoV N protein was able to inhibit the induction
of IFN-β promoter gene expression (114). They also showed that in response to Sendai
virus infection or polyI:C the N protein is able to block an ISRE promoter (114). This
finding indicates that the N protein exerts its effects on both IFN induction and IFNmediated signaling to downregulate the IFN system. Studies of the first nonstructural
protein of SARS-CoV nsp1 suggest that this protein utilizes several mechanisms to
antagonize Type I IFN production and signaling (191-193). Kamitami et al observed that
in human 293 cells, SARS-CoV infection suppresses IFN-β mRNA accumulation (192).
Using a two-pronged mechanism, SARS-CoV nsp1 mediates the degradation of host
mRNAs and inhibits the cellular translational machinery in infected cells (192,193).
Furthermore, nsp1 inhibits the phosphorylation of STAT1 (192). In addition to SARSCoV nsp1, nsp7 and nsp15 have both been shown to act as potential IFN antagonists but
are not well characterized (194).
Regulation of Innate Immunity by the PLpro Domain of Coronaviruses
Viruses encode proteases that can act as multifunctional proteins that not only
generate their mature proteins, which is an essential step in viral replication, but also can
play specific roles in the interaction of the virus with the host innate immune response, by
cleaving or disrupting the function of key host proteins important for antiviral immunity.
For example, the coxsackievirus B3 (CVB3) 3Cpro cysteine protease cleaves the innate
immune adaptor MAVS and TRIF as a strategy to disrupt Type I IFN responses (195).
Furthermore, hepatitis C virus (HCV) serine protease NS3/4A and hepatitis A virus
3ABC cysteine protease both use similar mechanisms to cleave MAVS, disrupting the
RLR signaling pathway, thus abolishing mitochondrial targeting of the adaptor protein
and ultimately suppressing antiviral innate immune responses (196-198). For these
viruses and many more, the catalytic activity of the viral proteases represents a unique
viral strategy to inhibit antiviral innate immune responses.
Whereas most CoVs contain two analogous enzymes called PLP1 and PLP2,
SARS-CoV utilizes one termed PLpro contained within nsp3, to process the aminoterminal end of the replicase polyprotein (3-5,120). In addition to recognizing its protease
activities, Sulea et al predicted that the PLpro of SARS-CoV possesses DUB activities
based on structural similarities with herpesvirus-associated ubiquitin-specific protease
(HAUSP), a cellular DUB enzyme (199). Thus, SARS-CoV’s predicted ability to
recognize the C terminus sequence of ubiquitin, which is common to ubiquitin-like
molecules, has led to the assumption that the Plpro domain may also cleave ubiquitin-like
molecules such as ISG15. Several studies purified the catalytic domain of PLpro and
demonstrated that PLpro proficiently removes di-ubiquitin and branched polyubiquitin
chains, cleaves ubiquitin-AMC substrates, and has deISGylating activity (135,139, 200,
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201). These studies were the first to characterize the multifunctional nature of coronaviral
PLPs. Since then, several groups have demonstrated the DUB and deISGylating activities
of HCoV-NL63, MHV, and most recently MERS-CoV papain-like proteases
(137,138,202). However, it is unclear if the DUB and deISGylating activities of
coronaviral PLPs play a role in the viral replication cycle.
Ubiquitination and ISGylation are post-translational modifications that are
essential for a wide variety of biological processes, including regulating the innate
immune responses to pathogens (203, 204). It has been shown in a cell culture system
that expression of ISG15 inhibited the release of HIV-1 virions from infected cells (205),
diminished alphavirus replication (206) and inhibited Influenza A virus gene expression
and replication in human cells (207). Furthermore, ISG15-deficient mice are more
susceptible to several human pathogens, including influenza A and B viruses,
herpesviruses, Chikungunya virus (CHIKV), vaccinia virus, and Sindbis viruses (208213). Several laboratories have highlighted proteases DUB activity-mediated innate
immune evasion by many virus groups such as arterviruses, picornaviruses, herpesviruses
and CoVs (186, 214). Ubiquitination and ISGylation are important elements of the host
antiviral innate immune response, and SARS-CoV PLpro has the ability to negatively
regulate these fundamental processes, an ability that may contribute to SARS
pathogenesis.
Several reports have identified coronaviral papain-like protease domains as
negative regulators of innate immunity, specifically IRF-3-dependent Type I IFN
responses. Antagonism of the IRF-3-dependent Type I IFN system by coronavirus PLPs
has been most extensively studied for the SARS-CoV PLpro. In 2007, Devaraj et al were
the first to report that SARS-CoV PLpro had the ability to inhibit type I IFN production.
It was shown that SARS-CoV PLpro mediated antagonism of type I IFN production
functions upstream of IRF-3 activation by interacting with IRF-3 and inhibiting its
phosphorylation, dimerization, and nuclear translocation. SARS-CoV PLpro was also
able to inhibit the activation of the IFN-β promoter in HeLa cells stimulated with SeV
infection or poly(I:C) treatment (186). It was also reported that the inhibition of the IFN
response was independent of the protease activity and that the PLpro had no inhibitory
effect on the NF-ĸB pathway (186). Subsequently, Frieman et al demonstrated that the
PLpro domain inhibits IRF-3-dependent induction of IFN-β (194). However, the
mechanism by which this occurs is controversial. Frieman et al confirmed that PLpro
inhibits the phosphorylation of IRF-3; however, in contrast to the study detailed above,
the authors demonstrated that there is no direct interaction between SARS-CoV PLpro
and IRF-3 (194). Mutagenesis of the active site at two different residues, which has been
shown to abolish catalytic activity, affected the PLpro antagonistic activity, but at varying
degrees, with some mutants maintaining the IFN antagonist ability, and others losing their
antagonistic activity. Interestingly, a variation in DUB activity of the mutants was also
observed, suggesting that the catalytic activity of PLpro may play a role in IFN
antagonism (165,194). However, HCoV-NL63 PLP2 has been shown to antagonize type I
IFN production independent of its catalytic and DUB activities (215).
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Studies detailing the IFN antagonist activity of MHV PLP2 domain have
demonstrated that PLP2 can deubiquitinate and inactivate IRF-3 to inhibit IFN induction
(216). Furthermore, the authors show that wild-type PLP2, but not the mutant PLP2 that
lacks the DUB activity, can block IFN induction, thus suggesting that the viral DUB
activity may be required for PLP2-mediated IFN antagonism (216). More recently, Wang
et al reported that MHV PLP2 antagonizes IRF-3 dependent signaling by targeting
TBK1, a kinase that induces phosphorylation and dimerization of IRF-3, and the authors
suggest that this mechanism is dependent on PLP2 DUB activity (202). Later studies
have also associated the ability of CoV PLPs to inhibit type I IFN induction with their
ability to antagonize stimulator of interferon genes (STING), a scaffolding molecule
required for the activation of IRF-3, and this ability is mediated by catalytic-dependent
and catalytic-independent activities (217, 218).
Remarkably, it was reported that deletion of the UBL domain at the amino
terminus of SARS-CoV PLpro led to a loss in IFN antagonistic function for both IRF-3
and NF-ĸB pathways; however, the protease and DUB activity remained intact (194).
However, the contribution of the UBL domain to the SARS nsp3 IFN antagonism was
not observed in the study by Clementz et al (215). Instead, when using purified wild-type
and Ubl mutant proteases, Mielech et al demonstrated that the Ubl domain adjacent to
PLP2 of MHV altered viral protease activity and stability. Furthermore, the authors
found that these mutations resulted in a decrease of virus replication and an obvious
attenuation of virulence (219). The relationship between the UBL domain present
alongside the PLP and the protease activity remains elusive. However, it is quite clear
that the Ubl domain may play a role in the pathogenesis of CoVs, and further studies are
needed to elucidate the role of coronavirus protease/DUB activity in PLP-mediated
interferon antagonism.
The underlying mechanisms that lead to the difference in IFN antagonism profiles
of the PLPs from different CoVs are not clearly understood. Moreover, it is not clear if
the catalytic activity of the PLpro is indispensable for functions unrelated to the
proteolytic processing of the replicase polyprotein. Additionally, the catalytic activity and
the DUB activity both depend on the same protease active site; therefore, it is difficult to
study them independently during virus infection. As such, no direct evidence has been
reported linking DUB activity to the suppression of PLpro-mediated innate immune
responses in virus-infected cells. It is also important to consider that a mutation of the
catalytic active site of the PLpro may not affect its complete ability to interact with
ubiquitin and ISG15 molecules in virus-infected cells; therefore, IRF-3-dependent
signaling could still be disrupted. Most importantly, the studies detailed above revealed
that SARS PLpro and other CoV PLP2 domains are Type I IFN antagonists.
Unless specified, the studies described above make use of constructs consisting of
just the PLpro domain and its transmembrane domain; however, in virus-infected cells,
we do not know if the PLpro is exposed to execute the IFN-antagonizing function in the
context of the full-length nsp3 protein. Thus, overexpression of the PLpro domain
construct may not reveal a complete profile of the PLpro IFN antagonist properties.
Therefore, examining the functional role of SARS-CoV PLpro should be in the context of
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the full-length nsp3, which to date has not been done. Therefore, although a wealth of
knowledge has been gained from these studies, it remains elusive whether the PLpro
impacts the IRF-3-dependent innate immune responses when expressed in the context of
the full-length nsp3 protein, which is the case in virus-infected cells.
Statement of Purpose
Within the 21st century, two novel human CoVs have emerged: SARS-CoV and
MERS-CoV, both of which cause a highly pathogenic respiratory disease in the lung and
are associated with high mortality rates. On the contrary, other previously known HCoVs,
such as OC43 and NL63, generally cause mild upper respiratory tract infections. The
emergence of MERS-CoV nearly ten years after the SARS-CoV pandemic demonstrates
the capacity of highly pathogenic CoVs to continue to spill over from zoonotic reservoirs
into the human population, with the potential to become pandemics. The emergence of
both SARS-CoV and MERS-CoV highlights the significance of understanding the
pathogenesis of Coronaviruses. Over the past 10 years, much has been learned about
highly pathogenic CoVs from the investigation of SARS-CoV, which aids in our efforts
to combat MERS-CoV; however, gaps in our understanding remain. It is well known that
the initial virus-host interactions may dramatically impact the course and/or outcome of
the infection. At present, the differences in the molecular and cellular mechanisms for
how human CoVs interact with the host innate immune system, resulting in less severe or
fatal outcomes, are poorly understood. Several reports have shown the papain-like
protease (PLP) domain of coronaviral nonstructural protein 3 (nsp3) as a potent IFN
antagonist by suppressing IRF-3-dependent innate antiviral defenses. The goal of this
dissertation is to understand the mechanism by which the full-length nsp3 protein of
different human coronaviruses regulates IRF-3-dependent innate immune responses.


The objective of Chapter 3 is to create an in-vitro system that can be used to
characterize the function of the full-length nsp3 protein of CoVs on the
antagonism of the host type I IFN responses. By investigating the function of the
full-length nsp3, I hope to assess whether the full-length nsp3 protein can
differentially regulate the IRF-3-dependent host innate immune responses and
whether there are any differences in this ability among different coronaviruses.



The objective of Chapter 4 is to determine whether the full-length nsp3 protein is
a major contributor to HCoVs antagonism of the interferon response and whether
this ability may be differentially regulated among the different HCoVs, thus
modulating the IRF-3-dependent pathways differentially.
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CHAPTER 2.

MATERIALS AND METHODS
Cell Lines

The Flp-In T-Rex expression system (Invitrogen) was utilized to generate
isogenic, stable HeLa cell lines exhibiting tetracycline-inducible expression of HcoVOC43-nsp3, HcoV-NL63-nsp3, MERS-CoV-nsp3, or wild type or mutant SARS-nsp3 by
a Saccharomyces cerevisiae-derived Flp recombinase-dependent DNA homologous
recombination event. Refer to chapter 3 for detailed procedures. Human embryonic
kidney (HEK) 293FT cells, were grown and maintained in Dulbecco’s modified Eagle
medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL
penicillin G, and 100 U/mL streptomycin in a humidified 37°C/5% CO2 incubator.
Plasmids
Conventional PCR and Quick-change site directed mutagenesis (Stratagene)
(using specific primers containing desired mutations) techniques were used to construct
N-terminal 2×HA-tagged and mutant forms of HCoV-OC43, HCoV-NL63, MERS-CoV,
and SARS-CoV nsp3 encoding plasmids in the pcDNA5/FRT/TO backbone (Invitrogen).
The primers and restriction enzymes used for construction and cloning of recombinant
plasmids are listed in Table 2.1. The following plasmids were kind gifts from the
indicated contributors; pcDNA3-FLAG TBK1 and pcDNA3-FLAG IKK (from Kate
Fitzgerald) (158); pIFN-β-luc. and GFP-IRF3-5D (from Rongtuan Lin) (220). The
identities of all plasmids were confirmed by DNA sequencing.
Immunoblot Analysis
Cell lysates were prepared and quantified for protein concentration and subjected
to immunoprecipitation (IP) and immunoblot analysis as previously described (221, 222).
However briefly, to confirm expression of proteins equivalent amounts of whole cellular
extracts were prepared, separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis (PAGE) in a 7.5 % or 10% polyacrylamide gel. After electrophoresis,
proteins were transferred to a nitrocellulose blotting membrane (Amersham) in transfer
buffer for 1 hr. The membrane was blocked by incubation in phosphate-buffered saline
(PBS) containing 3% dried milk for 1 h. The following monoclonal (mAb) and
polyclonal (pAb) antibodies were utilized: rabbit anti-ISG56 pAb (generated by
immunizing rabbits with a keyhole limpet hemocyanin-coupled peptide spanning amino
acids 2 to 19 of human ISG56) (221), mouse anti HA mAb (12ca5 hybridoma culture
supernatant), mouse anti-VSV-IN mAb (NIH), rabbit phosphorylated IRF3 pAB (cell
signaling), or mouse anti-actin mAb (Sigma) in 3% milk–PBS at a dilution of 1:500,
1:50, 1:1000, and 1:5000 respectively. These incubations were done at 4°C overnight or
at room temperature for 1 to 2 hours. After three 5-min washes with PBS, membranes
were reacted with a peroxidase-conjugated secondary goat anti-rabbit and goat anti-

25

Table 2.1.
NSP3
protein
OC43NSP3N

Primers used to construct the full-length NSP3 proteins.
Primer name

Sequence (5’-3’)

OC43BamHINSP3-F
OC43NotINSP3N-R

cgcggatccatgggaaggcgtgttacatttaagg
ctgacgcggccgcttacaaggctttaatttgagcaac

OC43NSP3C

OC43BamHINSP3C-F
OC43XHoINSP3-R

cgcggatccatggagtgtactggaggcatagata
cttcactcgagtagttaacctcctttaagactaaagggtgta

NL63NSP3N

NL63AgeINSP3-F
NL63NotINSP3N-R

gcaccggtatgggtaaaatatctttttctgatgat
cttcagcggccgcttaatcatttatcgatggtacaacaca

NL63NSP3C

NL63 AgeINSP3C-F
NL63XHoINSP3-R

cgcttaccggtatggtaccatcgataaatgatctttct
cttcactcgagttaagcaccctgttttgcaactatac

MERSNSP3N

MERSBamHINSP3-F
MERSNheINSP3N-R

cgcggatccatggcacctgtaaaaaaagtagcc
ctgacgctagcttagtctgtacacacaaaaacagtaaaac
c

MERS NSP3C1

MERSBamHINSP3C1F
MERSXHoINSP3C1-R

cgcggatccatggtgtgtacagacaactctgctaac
cttcactcgagttaagagattcctaggtaagctctaac

MERS NSP3C2

MERSBamHINSP3C2F
MERSXHoINSP3C2-R

cgcggatccatggcttacctaggaatctcttctgct
cttcactcgagttaaccaccaacaattttgttagcag

SCoVNSP3N

SCoVBamHINSP3-F
SCoVNotINSP3N-R

cttcaggatccatggcaccaattaaaggtgtaaccttg
cttcagcggccgcttaatcaaagctagcatttggtaatggtt
g

SCoVNSP3C

SCoVBamHINSP3C-F
SCoVXHoINSP3-R

cttcaggatccatgccaaatgctagctttgataatttcaaac
cttcactcgagttaaccacccttgagtgagattttagt

SCoVdelPLPN

SCoVdelPLPNSP3-F
SCoVdelPLPNSP3-R

ctcgatggagttacttacacagag
ctcacgcagggataagagact
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mouse immunoglobulin G pAbs (Southern Biotech) at a dilution of 1:8000 for 1hr at
room temperature. After two 5 min washes and one 10 wash, protein bands were then
visualized with the enhanced chemiluminescence (ECL) detection system as
recommended by the manufacturer (Millipore), followed by exposure to Kodak Biomax
film
Sendai Virus (SeV) Infection, and Poly (I-C) Treatment
Where indicated, cells were infected with 100 hemagglutinin units (HAU)/ml of
SeV (Cantell strain, Charles River Laboratories) for 16 h prior to cell lysis for luciferase
reporter assay and/or immunoblot analysis as described previously (221-223). For poly
(I-C) (Sigma) treatment, poly (I-C) (Sigma) was added directly to the culture medium at
25µg/ml (M-pIC) and loaded onto the cells for the indicated time period.
Transfection and IFN-β Luciferase Reporter Gene Assay
Luciferase assays were performed in 48-well plates (Greiner Bio-one) seeded with
20000 cells per well in triplicates, cells were then un-induced or induced with tetracycline
2ug/ml for 48hrs before transfection. Cells were then transfected in triplicate with the
IFNβ-Luc (IFNB-pGL3) reporter plasmid (80 ng), and pRL-TK (20ng) (internal control
to normalize the activity of the IFNβ-Luc reporter plasmid transfection efficiency)
(Promega), using Lipofectamine 3000 transfection reagents, as per the manufacturer’s
instructions (220). Twenty four hours later, transfected cells were mock-treated, treated
with poly (I-C) (Sigma) for 10 h, or infected with SeV (Cantell strain, Charles River
Laboratories) for 16 h before cell lysis. IFN-β promoter activities were determined by
assaying for both firefly luciferase and renilla activities. Data were expressed as mean
relative luciferase activity (luciferase activity divided by renilla luciferase activity) with
standard deviation from a representative experiment carried out in triplicate. A minimum
of three independent experiments were performed to confirm the results of each
experiment.
Vesicular Stomatitis Virus Luciferase Reporter Gene Assay
VSV-Luc is a recombinant firefly luciferase-encoding vesicular stomatitis virus,
in which in infected cells replication can be monitored by assaying for luciferase activity
(224). The VSV luciferase assay were performed in 24 well plates (Greiner Bio-one)
seeded with 40,000 cells per well in triplicates, cells were then un-induced or induced
with tetracycline 2ug/ml for 48hrs. Where indicated, cells were mock-treated or treated
with poly (I-C) (GE Health) or transfected with 2µg of HCV RNA replicon (HCV
genotype 2a strain JFH1-1581) using Lipofectamine 3000 reagents (Invitrogen) per the
manufacturer’s instructions for 8-10 hrs. Cells were then infected with rVSV-Luc. at an
MOI of 0.1 and virus was removed after 1hr. At 6-8 hours post infection, luminescence
was measured using Steady-Glo firefly luciferase reagent (Promega) according to the

27

manufacturer’s instructions. The luminescence values were recorded on a Glomax 20/20
Luminometer (Promega)
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CHAPTER 3. GENERATION OF STABLE CELL LINES INDUCIBLY
EXPRESSING HUMAN CORONAVIRUSES (COV) NONSTRUCTURAL
PROTEIN 3 (NSP3)
Introduction
There are many viruses that cause severe diseases for which there are neither
vaccines nor effective antiviral therapies. As a result, millions of people lack treatment
and preventive measures for these virally induced diseases that may lead to fatal
outcomes. Thus, many viral diseases continue to be a challenging global health issue.
Severe acute respiratory syndrome (SARS), the first epidemic of the 21st century, was
caused by a novel human coronavirus (HCoV), referred to as SARS-associated
coronavirus (SARS-CoV). In humans, SARS outbreak was the first paradigm of serious
illness caused by a CoV (1, 5). Moreover, the SARS-CoV epidemic serves as an example
of the quickness of virus spread expedited by air travel, mass transit and increased
population density nowadays. Unfortunately, there are no approved vaccines or therapies
for humans to control SARS-CoV, or any of the HCoVs known to date. In order to design
successful treatment and prevention methods to virally induced diseases, an in-depth
understanding of viral components and their contribution to viral pathogenesis is
essential.
Human coronaviruses were initially considered to be agents of the common cold
and caused little mortality (1, 12-15). HCoV-OC43 and HCoV-229E were the first two
HCoVs identified. These two are responsible for about 30% of common colds worldwide
although the molecular basis of disease was not well studied. However, the SARS-CoV
epidemic of 2003 demonstrated the ability of a novel CoV to quickly to spread globally
in immunologically naïve human populations, causing over 8000 cases and a ~10 %
mortality rate in 29 countries (5, 21). Evidence suggests that SARS-CoV most likely
evolved from viruses circulating within Chinese horseshoe bats, which are believed to be
the natural animal reservoirs (31-33). The SARS outbreak sparked a keen interest in the
disease pathogenesis of CoVs and led to an intense search for additional HCoVs that
could cause severe disease in humans. Within the following couple of years, HCoVNL63 and HCoV-HKU1, two new HCoVs causing mild disease in humans, were
identified (22, 23). Most recently, another novel highly pathogenic CoV, which can
cause severe disease in humans, emerged suddenly in the Middle East region and was
designated MERS-CoV (24-26). Likewise, MERS-CoV emerged from a zoonotic
reservoir to infect humans (34-37). To date, there are 6 known HCoVs. There is an
obvious difference in the severity of the disease outcome among HCoVs. Four of these
are endemic in humans and are mainly associated with mild respiratory illnesses whereas
the other two CoVs present as emerging infections causing a severe respiratory syndrome
leading to fatality, thus highlighting the capacity of severe disease potential of the CoV
family (1, 5,12-15, 21, 24-26). Insight into how CoVs regulate the host cell is critical for
a full understanding of the molecular mechanisms that contribute to the severe disease
state caused by these viruses.
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Coronaviruses, a genus belonging to the Coronaviridae family, are positive-strand
enveloped RNA viruses that can infect a variety of animal hosts, including humans (1, 2,
5). They have an incredibly large single-stranded genome, the largest of all RNA viruses
known to date (2). Coronaviruses encode large replicase polyproteins that are processed
by two virally encoded proteases, i.e., the papain-like protease (PLP) and a 3C-like
protease (3CLpro), to generate 15 or 16 nonstructural proteins that are involved in viral
replication (1-6). For these viruses, the PLP is essential for processing the amino-terminal
end of the replicase polyproteins (1-6, 118, 120). All human coronaviruses, with the
exception of SARS-CoV and MERS-CoV, contain two PLPs to process the aminoterminal portion. It is well known that when two PLPs are encoded within the
coronavirus replicase polyprotein, PLP2 has similar characteristics to SARS-CoV PLpro
(120, 132). The investigation of the PLP of SARS-CoV has illustrated the multifunctionality of coronaviral PLPs. Since PLPs are essential for coronaviral replication,
they are attractive targets for antiviral treatments. The PLP domain is located within the
largest replicase subunit, nsp3. Nsp3 is a multi-domain protein, essential in the formation
of double membrane vesicles (DMV), a hallmark of coronavirus replication (122-125).
Earlier reports demonstrated that the PLP of nonstructural protein 3 (nsp3), functions not
only as a viral protease, but also possesses deubiquitinating (DUB) and deISGylating
activities (134-139, 199, 201), which are suggested to participate in regulation of the host
innate immune response to viral infection.
Subsequent reports have shown the papain-like protease (PLP) domain of
coronaviral nonstructural protein 3 (nsp3) as a potent IFN antagonist by suppressing IRF3-dependent innate antiviral defenses. Devaraj et al first reported that SARS-CoV PLP
inhibits IRF3 activation (186), which was corroborated by reports by other groups (194,
202, 216). Of note, studies investigating the role of the PLpro domain in regulating the
host innate immune defenses have mainly relied on the use of transient transfection of
mammalian cell lines with plasmids encoding truncated nsp3 PLP domain constructs. It is
likely that this is due to the extremely large size of the nsp3 protein, which made it very
difficult to clone and express in mammalian cells.. Although transient transfection
provides a faster way of expression of a protein, the efficiency of transfection typically
decrease with very large plasmids, making it difficult to achieve comparable expression
of proteins among each experiment. Stable and regulated gene expression is a very useful
tool to study further and characterize the function of a gene product. Since the 1990’s,
tetracycline-regulated expression systems have been widely used for inducible protein
expression in cell culture (225-227). The construction of stable inducible cell culture
systems may greatly facilitate the analysis of the function of genes and gene products.
More importantly, it has not been shown whether the CoV PLP domain impacts
IRF-3 signaling when expressed in the context of the full-length nsp3 protein, which may
lead to a better understanding of the PLP-mediated function of the nsp3 protein in virusinfected cells. Thus, it is helpful to establish in-vitro cell systems with stable and
comparable nsp3 expression, for the study of nsp3 interactions with the host innate
immune responses. Understanding if the nsp3 protein is a bona fide contributor to human
CoVs antagonism of the host innate immune response, and if this ability may be
differentially regulated among different HCoVs, will provide insight into essential
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virulence factors contributing to CoVs disease outcomes and pathogenesis. To understand
better the functional role of the nsp3 protein of different HCoVs in regulating IRF-3dependent innate immune responses, I used an Flp-In-T-Rex expression system
successfully to create stable cell lines that express, in a tetracycline-regulated fashion, the
full-length nsp3 protein of HCoVs OC43, NL63, MERS-CoV, and SARS-CoV
respectively.
Materials and Methods
Construction of CoV-nsp3 Expression Plasmids
Primers specific for the N and C terminal regions of the nsp3 proteins were used
to construct the plasmid vectors encoding full length nsp3 protein (HCoV-OC43, HCoVNL63, MERS-CoV, and SARS-CoV, respectively) and the PLP-deletion mutant nsp3
protein of SARS-CoV (Table 2.1). Briefly, the N and C terminal fragments of nsp3s were
amplified by PCR from corresponding nsp3 cDNAs. The cDNA source for HCoV-OC43
nsp3 was total RNA extracted from monkey kidney epithelial cells (BSC-1) infected with
HCoV-OC43 (ATCC VR-1558). HCoV-NL63 (Amsterdam I) RNA from B.E.I.
resources was as the starting material for HCoV-NL63 cDNA and MERS-CoV cDNA
was kindly provided by Dr. Heinrich Feldmann’s lab at the National Institute of Health
(NIH) Rocky Mountain Laboratories. The N and C terminal fragments of SARS-CoV
nsp3 cDNA was amplified from the full-length nsp3 cDNA of SARS-CoV nsp3 (a gift
from Dr. Marc Wathelet, Lovelace Respiratory Research Institute) (191). The PCR
products was digested with appropriate restriction enzymes, purified after gel
electrophoresis, and ligated into pcDNA5/FRT/TO (Invitrogen), in which nsp3 was fused
to an N-terminal 2XHA epitope tag. Subsequently, the N- and C-fragments were joined
together to construct the full length nsp3 protein-encoding plasmids, also in the
pcDNA5/FRT/TO backbone. Constructs were digested with restriction enzymes to verify
positive recombinant plasmids Figure 3.1. Subsequently, constructs were sequenced to
verify incorporation and identity of nsp3 cDNAs.
Cell Culture and Generation of Stable Cell Lines
HeLa Flp-In T-Rex cells (a gift from Stephen Taylor at University of Machester)
(228) were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 100 U/mL penicillin G, 100 U/mL streptomycin, and 2 µg/mL Blasticidin.
The cells were co-transfected with the pOG44 vector, which expresses the Flp
recombinase under control of the human CMV promoter, and individual CoV nsp3
encoding plasmids, i.e., pcDNA5/FRT/TO/HA-HCoV-OC43-nsp3,
pcDNA5/FRT/TO/HA-HCoV-NL63- nsp3, pcDNA5/FRT/TO/HA-MERS-CoV- nsp3,
pcDNA5/FRT/TO/HA-SCoV- nsp3 and pcDNA5/FRT/TO/HA-SCoV-nsp3-delPLP,
respectively. The pcDNA5/FRT/TO-derived expression plasmids contains a FRT site
linked to the hygromycin resistance gene for Flp recombinase-mediated integration and
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selection of stable cell lines expressing individual CoV nsp3 protein under control of a
tetracycline-regulated CMV/TetO2 promoter (225, 229). The pOG44 and the
pcDNA5/FRT/TO/HA-CoV-nsp3 expression constructs were co-transfected in a 9:1 ratio
using Lipofectamine 3000 reagent (Invitrogen) as described by the manufacturer. Two
days after transfection the cells were trypsinized and transferred to 10-cm dishes. After
cells had attached, the growth media was replaced with a selection media containing 200
µg/mL Hygromycin B and 2 µg/mL Blasticidin (Invitrogen). The selection media was
changed every 3 to 4 days until colonies emerged and control cells (untransfected HeLaFlp In T-Rex cells) were all dead. Initial experiments were performed using pooled
Hygromycin B resistant colonies, which by nature of the Flp-In system were isogenic. In
selected experiments involving HeLa-Fit-HCoV OC43-nsp3, HeLa-Fit-HCoV NL63nsp3, and HeLa-Fit-MERS CoV-nsp3 stable expressing cells were also performed using
individual Hygromycin B resistant clones. To induce nsp3, cells were exposed to 2 µg/ml
of tetracycline, harvested at 48hrs post Tet induction and lysed. Western blot analysis
was performed to demonstrate inducible expression of nsp3.
Western Blot Analysis
To confirm expression of nsp3 proteins, equivalent amounts of whole cellular
extracts were prepared, separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis (PAGE) in a 7.5 % or 10% polyacrylamide gel. After electrophoresis,
proteins were transferred to a nitrocellulose blotting membrane (Amersham) in transfer
buffer for 1 hr. The membrane was blocked by incubation in phosphate-buffered saline
(PBS) containing 3% dried milk for 1 h. NSP3 were detected via their HA-epitope tags
with a monoclonal antibody (mAb) against the HA tag (Invivogen) or a mouse anti-HA
mAb (clone 12ca5 hybridoma culture supernatant) in 3% milk–PBS at a dilution of
1:2000 and 1:50, respectively. Expression of SARS-CoV nsp3 protein was also
confirmed by immunoblotting with a rabbit pAb against nsp3 (Rockland). ISG56 was
detected via rabbit anti-ISG56 pAb (221) in 3% milk–PBS at a dilution of 1:500. These
incubations were done at 4°C overnight or at room temperature for 1 to 2 hours. After
three 5-min washes with PBS, membranes were reacted with a peroxidase-conjugated
secondary goat anti-mouse or secondary goat anti-rabbit immunoglobulin G pAbs
(Southern Biotech) at a dilution of 1:8000 for 1 hr at room temperature. After two 5 min
washes and one 10 wash, protein bands were then visualized with the enhanced
chemiluminescence (ECL) detection system as recommended by the manufacturer
(Millipore), followed by exposure to Kodak Biomax film.
Sendai Virus (SeV) Infection
Where indicated, cells were infected with 100 hemagglutinin units (HAU)/ml of
SeV (Cantell strain, Charles River Laboratories) for 16 h prior to cell lysis for
immunoblot analysis.
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Results
Identification of Recombinant pcDNA5/FRT/TO/HA-CoV Nsp3 Plasmids by
Restriction Enzyme Analysis
In order to express the full-length nsp3 protein of HCoVs OC43, NL63, MERSCoV and SARS-CoV, I first sub-cloned each nsp3 fragment into the multiple cloning
sites of the mammalian expression plasmid pcDNA5/FRT/TO/HA. The sizes of
pcDNA5/FRT/TO/HA, and the cDNA fragment of OC43- nsp3, NL63- nsp3, MERSnsp3, SARS- nsp3 and SARS-nsp3-delPLpro are 5.2Kb, 5.7Kb, 4.7Kb, 5.7Kb, 5.8Kb,
and 4.8Kb, respectively. After the completion of standard molecular biology techniques
to construct the recombinant plasmids, positive transformants were analyzed by
restriction digestion of miniprep DNA. Due to the size similarities of the mammalian
expression vector and CoV-nsp3 cDNA fragments, to identify successful recombinant
clones, recombinant pcDNA5/FRT/TO/HA-CoV-nsp3 plasmids were digested with
multiple restriction enzymes to separate the expression vector and CoV-nsp3 fragments.
Nine pcDNA5/FRT/TO/HA-OC43-nsp3 minipreps were digested with BamHI,
BsrGI, and XhoI. Fragments of 5.2Kb, 3.6Kb, and 2.1Kb were generated by each
miniprep, suggesting all nine minipreps were positive clones Figure 3.1A. Eight
pcDNA5/FRT/TO/HA-NL63-nsp3 plasmids were cleaved with AgeI, ClaI, and XhoI.
Fragments of 5.2Kb, 2.8Kb, and 1.9Kb were generated by five of the eight minipreps
Figure 3.1B. Six pcDNA5/FRT/TO/HA-MERS-nsp3 plasmids were cleaved with AvrII,
BamHI, and XhoI. Fragments of 5.2Kb, 4.1Kb, and 1.6Kb were generated by four of the
minipreps Figure 3.1C. Two restriction enzyme digestion reactions were used to verify
pcDNA5/FRT/TO/HA-SARS- nsp3 plasmids. Two plasmids were digested with PmeI,
generating fragments of 5.9Kb and 5.0Kb and EcoRI and SnaBI generating fragments of
4.2Kb, 3.8Kb and 2.8Kb, suggesting that both were positive clones Figure 3.1D.
To demonstrate the difference in fragment size, three pcDNA5/FRT/TO/HASARS-nsp3-delPLP plasmids along with two pcDNA5/FRT/TO/HA-SARS-nsp3 wt
mini-prep plasmids, were cleaved with BamHI, NheI and XhoI. Fragments of 5.2Kb,
2.3Kb, and 2.5Kb were generated, confirming lane 6 to be a positive mini-prep for
pcDNA5/FRT/TO/HA-SARS-nsp3-delPLP Figure 3.1E. Restriction enzyme mapping
showed that the full length of each CoV-nsp3 and deletion mutant of SARS-nsp3 product
had been successfully cloned into the specified restriction sites in the
pcDNA5/FRT/TO/HA vector, and the sizes of the recombinant plasmids were consistent
with expectation. Sequence analysis confirmed the sequence and orientation of the
inserted CoV-nsp3 cDNAs in the pcDNA5/FRT/TO/HA vector.
Transient Expression of CoVs-Nsp3 Recombinant Plasmids
In an effort to establish stable Tet-regulated inducible cell lines, I first determined
if the positive clones of each CoV-nsp3 plasmid allowed expression of the full-length or
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Figure 3.1. Restriction enzyme digestions of recombinant pcDNA5/FRT/TO/HACoV-nsp3 expression plasmids
(A). Lane 1: 1Kb marker, Lane 2-10: pcDNA5/FRT/TO/HA-OC43-nsp3 minipreps,
cleaved with BamHI, BSRGI, and XhoI, fragments of 5.2Kb, 3.6Kb, and 2.1Kb indicate
positive clones. (B) Lane 1: 1Kb marker, Lane 2-9: pcDNA5/FRT/TO/HA-NL63-nsp3
minipreps, cleaved with AgeI, ClaI, and XhoI. Fragments of 5.2Kb, 2.8Kb, and 1.9Kb
indicate positive clones. (C) Lane 1: 1Kb marker, Lane 2-7: pcDNA5/FRT/TO/HAMERS-nsp3 minipreps, cleaved with AvrII, BamHI, and XhoI. Fragments of 5.2Kb,
4.1Kb, and 1.6Kb indicate positive clones. (D) Lane 1: 1Kb marker, Lane 2-5:
pcDNA5/FRT/TO/HA-SARS-nsp3 minipreps, cleaved with PmeI, fragments of 5.9Kb
and 5.0Kb and ECoRI and SnaBI generating fragments of 4.2Kb, 3.8Kb and 2.8Kb
indicate positive clones. (E) Lane 1: 1Kb marker, Lane 2-3: pcDNA5/FRT/TO/HASARS-nsp3 wild-type minipreps, Lane 4-6: pcDNA5/FRT/TO/HA-SARS-nsp3-delPLpro
minipreps, cleaved with BamHI, NheI and XhoI, fragments of 5.2Kb, 2.3Kb, and 2.5Kb
indicate positive clones.
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mutant nsp3 protein in transiently-transfected cells. The expression plasmid encoding
viral nsp3 is N-terminally tagged with two copies of HA tag in the pcDNA5/FRT/TO
backbone (Invitrogen); therefore, each CoV-nsp3 was detected by using an anti-HA
antibody. After each construct was developed, I assayed for transient expression of the
CoV-nsp3 protein. HEK293FT cells were transfected with two micrograms of each
recombinant plasmid DNA, 48 hrs after transfection cells were assayed for expression.
Using a monoclonal anti-HA antibody Western Blot analysis confirmed that recombinant
plasmids gave rise to expression of the full-length OC43-nsp3, NL63-nsp3, MERS-nsp3,
and SARS-nsp3 wt and mutant proteins, respectively Figure 3.2A-3.2E. The molecular
weight of each nsp3 proteins are 212 KDa, 173 KDa, 209 KDa, 213 KDa, and 178 KDa
respectively. The molecular weight of each nsp3 protein was consistent with the
expected size.
Establishment Stable Cell Lines Using the Flp-In T-Rex System
A system that allows stringent inducible regulation of gene expression in
mammalian cells is a valuable tool for the functional characterization of genes. The most
widely used inducible protein expression systems are those regulated by tetracycline
(Tet) and its derivatives. In 1992, Gossen et al first described a Tet promoter activating
system for regulating individual genes in mammalian cells (225). Since then, the
tetracycline-regulated gene expression system has gained wide acceptance and has been
proven to work in both cell lines and mouse models; nonetheless, this system has
undergone several modifications (227, 230-233). The Flp-In-T-Rex system (Invitrogen)
is designed to generate cell lines that stably express proteins of interest in an isogenic and
inducible fashion. This unique feature is due to the fact that the gene of interest (GOI) is
integrated into the chromosome at a specific site, thus eliminating the possible variation
in expression levels or patterns that may be due to random integration into the
chromosome. Furthermore, cells can be grown without expression of the protein of
interest until such time as it is needed. The ability to induce expression by addition of Tet
to the culture medium has several advantages over either transient transfection or the
generation of constitutively expressing stable cell lines. Thus, I used the Flp-In-T-Rex
expression system successfully to generate stable cell lines that express, in a tetracyclineregulated fashion, the full-length nsp3 protein of HCoVs OC43, NL63, MERS-CoV and
SARS-CoV, respectively.
The Flp-In T-Rex-293 system cell line, based upon a derivative of human 293
embryonic kidney fibroblasts, is widely used by investigators. However, owing to their
physiological properties, in particular their intact innate immune signaling pathways, we
selected the Flp-In T-Rex-HeLa system based upon HeLa cells. The generation of the
HeLa-Flp-In-CoV-nsp3 cell lines requires that the parental cell lines HeLa-Flp-In-T-Rex
cells (234) are co-transfected with two plasmids, one containing the gene of interest
expressing the tetracycline repressor, and the other containing an Flp Recombination
Target (FRT) site. After verifying transient expression of the CoV-nsp3 constructs, each
clone that expressed the highest level of CoV-nsp3 protein, based on Western blot
analysis, was chosen to co-transfect with the pOG44 plasmid, an Flp recombinase
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Figure 3.2. Transient expression of recombinant pcDNA5/FRT/TO/HA-CoVnsp3 expression plasmids.
Unless noted, HEK293FT cells were transfected with 2 µg of pcDNA5/FRT/TO/HACoV-nsp3 mini-preps. 48 hrs post transfection cell lysates were harvested, and expression
of each CoV-nsp3 protein was detected using a monoclonal anti-HA antibody, analyzed
by Western blotting (A) Lane 1: Mock, Lane 2-7:pcDNA5/FRT/TO/HA-OC43-nsp3 (B)
Lane 1: Mock, Lane 2-9:pcDNA5/FRT/TO/HA-NL63-nsp3 (C) Lane 1: Mock, Lane 2-5:
pcDNA5/FRT/TO/HA-MERS-nsp3 (D) Lane 1: Mock, Lane 2-3: pcDNA5/FRT/TO/HASARS-nsp3 (E) HEK293FT cells expressing 2.5 µg of DNA Lane 1: Mock, Lane 2:
pcDNA5/FRT/TO/HA-SARS-nsp3 Lane 3: pcDNA5/FRT/TO/HA-SARS-nsp3-delPLP.
Mock: No transfection
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expression plasmid, into HeLa-Flp-In-T-Rex cells. Upon integration of the recombinant
plasmid into the FRT site, the cells were rendered hygromycin resistant, allowing
selection of the required integrants with hygromycin. For each cell line, after 2-3 weeks
of the selection process, the polyclonal population of cells was pooled, expanded and
using a monoclonal anti-HA antibody screened for tetracycline-regulated expression of
the nsp3 protein Figure 3.3A-3.3E. Established cell lines were generated and
characterized independently and designated HeLa-Fit-OC43-nsp3, HeLa-Fit-NL63-nsp3,
HeLa-Fit-MERS-nsp3, HeLa-Fit-SCoV-nsp3, and HeLa-Fit-SCoV-nsp3-delPLpro,
respectively. In addition, it was observed that the overall growth kinetics of each nsp3expressing cell line was similar to that of the parental HeLa-Flp-In T-Rex cells,
indicating that the CoV-nsp3 expression has no demonstrable effect on cell growth (data
not shown). These observations supports their potential use as a tool to study the function
of the full-length CoV-nsp3 proteins.
Characterization of Human Coronaviruses Full-Length Nsp3 Inducible Cell Lines
Each cell line was analyzed by immunofluorescence (IFA) staining, using an antiHA monoclonal antibody, to further examine CoV-nsp3 expression levels. In the absence
of tetracycline, each cell line exhibited no detectable nsp3 protein. Upon addition of
tetracycline, each cell line demonstrated nsp3 expression, suggesting that tetracycline
exerted a tight control over the expression of CoV-nsp3 (data not shown). As expected, I
observed a cytoplasmic localization pattern for each CoV-nsp3 protein (data not shown).
However, once all cell lines were generated and examined alongside each other, there
was an obvious difference in the signal intensity and percentage of cells that expressed
each CoV-nsp3 (data not shown). The percentage of cells expressing SARS-nsp3 was far
greater in number than was the percentage of cells expressing HCoV-OC43, HCoVNL63, and MERS-CoV nsp3 proteins (data not shown). Although each cell line was
generated in the same manner, these results suggest that the CoV-nsp3 stable expressing
cell lines are not expressing at comparable levels.
In an effort to establish stable cell lines with comparable expression, new Tetinducible MERS-CoV, HCoV-OC43, and HCoV-NL63-nsp3 stable expressing cell lines
were produced by selecting and expanding individual clones and pooled populations, as
indicated previously. Unexpectedly, upon the addition of Tet for the pooled population,
HeLa-Fit-OC43-nsp3 and HeLa-Fit-NL63-nsp3 stable cells still demonstrated a low
percentage of cells expressing nsp3 (data not shown). Furthermore, in the presence of
Tet, stable cells generated from expanding individual clones did not result in an increase
in HCoV-OC43 and HCoV-NL63 nsp3 expression (data not shown). However, selecting
individual colonies to generate HeLa-Fit-MERS-nsp3 stable cells revealed promising
results. Clone 1 of HeLa-Fit-MERS-nsp3 stable cells demonstrated higher expression of
MERS-nsp3 in the presence of Tet, when compared to the pooled HeLa-Fit-MERS-nsp3
stable cells (data not shown).
Ideally, regulation of gene expression can be controlled by adding different
concentrations of the inducers (234). Therefore, while the expression of HeLa-Fit-MERS-

37

Figure 3.3.

Tet-inducible expression of nsp3 in stable cell lines.

Cells were grown for 48 hrs in the absence (Tet-) (lane 1) or presence (Tet+) (lane 2) of
2µg/ml Tet treatment. Using an anti-HA antibody, the expression of CoV-nsp3 protein
was analyzed by Western blotting. (A) HeLa-Fit-OC43-nsp3 cells (B) HeLa-Fit-NL63nsp3 cells (C) HeLa-Fit-MERS-nsp3 cells (D) HeLa-Fit-SCoV-nsp3 cells (E) HeLa-FitSCoV-nsp3-delPLpro cells. Beta actin was used as a loading control.
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CoV-nsp3 stable cells was not comparable to that of HeLa-Fit-ScoV-nsp3 cells, I
investigated dose-dependent inducibility of CoV-nsp3 expression between the two cell
lines. Since Tet-inducible expression of HeLa-Fit-ScoV-nsp3 cells resulted in robust
expression of SARS-nsp3, to generate similar levels of expression, concentration
dependency was examined by inducing SARS-nsp3 with different concentrations of Tet
(0.1-1µg/ml) for 48 hrs. SARS-nsp3 expression levels that were induced at low
concentrations of Tet (0.2-1µg ug/mL) were still higher than MERS-nsp3 expression
levels induced at 2µg/ml of Tet, a concentration that has proven to be optimal in the use
of the Tet system (data not shown). These findings suggest that for the Tet concentration
range tested, there was not a concentration-dependent decrease in the amount of SARSnsp3 protein induced.
The nsp3 protein is not well conserved between coronaviruses (128). Thus, it
must be considered that the CoV-nsp3 proteins are being degraded or may have different
turnover rates. To examine this aspect, I assayed for transient expression of each CoVnsp3 protein, using the CoV-nsp3 expression construct used to generate the stable
expressing cell lines. HEK293T cells were transfected with two micrograms of each
recombinant plasmid, 48 hrs after transfection cells were assayed for expression of HAnsp3. Using a monoclonal anti-HA antibody Western Blot analysis demonstrated that the
transient CoV-nsp3 protein expression levels were obviously different Figure 3.4A. At a
short exposure time, HCoV-OC43, MERS-CoV and SARS-CoV-nsp3 protein expression
was observed Figure 3.4A. In contrast, HCoV-NL63-nsp3 protein expression was only
observed after prolonged exposure of the Western blot Figure 3.4B. Although gene
expression is controlled at many levels, it is possible that there are differences in the
CoV-nsp3 mRNA transcript levels. It is also possible that the codons for each CoV nsp3
differ in their efficiency in expression in human cells. Until comparable expression can
be demonstrated, HeLa-Fit-OC43-nsp3, HeLa-Fit-NL63-nsp3, and HeLa-Fit-MERS-nsp3
stable cells will not be utilized further to characterize the role of these CoV nsp3s in
regulation of the host innate immune response.
Furthermore, comparable expression was not achieved when 293-Fit-T-Rex, a
derivative of human embryonic kidney 293 cells, was used as the founder line to generate
SARS-CoV-, MERS-CoV-, HCoV-OC43-, and HCoV-NL63-nsp3 Tet inducible cell
lines (data not shown). Thus my subsequent studies were focused on SARS-CoV nsp3.
Importantly, HeLa-Fit-derived, Tet-regulated stable cells allowed comparable expression
of WT and delPLP nsp3 of SARS-CoV Figure 3.5. The observation that other CoV-nsp3
stable cells failed to express nsp3 at levels comparable to SARS-CoV nsp3, suggesting
that SARS-CoV codon is optimal for expression in human cells. Therefore, we used
HeLa-Fit-ScoV-nsp3 cells to gain better insight into the role of nsp3 in the regulation of
host antiviral innate immune responses
Discussion
The inducible expression of protein of interest in mammalian cells provides an
invaluable opportunity to examine protein functions. The Tet-regulated expression
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Figure 3.4. Transient expression of recombinant pcDNA5/FRT/TO/HA-CoVnsp3 expression plasmids used to generate Tet inducible stable cells.
(A) Short exposure of HEK293T cells were transfected with 2 µg of
pcDNA5/FRT/TO/HA-CoV-nsp3 mini-preps. 48 hrs post transfection cell lysates were
harvested, and expression of each CoV-nsp3 protein was detected using a monoclonal
anti-HA antibody, analyzed by Western blotting. Lane 1: Mock, Lane
2:pcDNA5/FRT/TO/HA-OC43-nsp3, Lane 3: pcDNA5/FRT/TO/HA-NL63-nsp3, Lane
4: pcDNA5/FRT/TO/HA-MERS-nsp3, Lane 5 pcDNA5/FRT/TO/HA-SARS-nsp3 Mock:
No transfection. Actin was used as loading control. (B) Long exposure of HEK293T cells
were transfected with 2 µg of pcDNA5/FRT/TO/HA-CoV-nsp3 mini-preps. 48 hrs post
transfection cell lysates were harvested, and expression of each CoV-nsp3 protein was
detected using a monoclonal anti-HA antibody, analyzed by Western blotting. Lane 1:
Mock, Lane 2:pcDNA5/FRT/TO/HA-OC43-nsp3, Lane 3: pcDNA5/FRT/TO/HA-NL63nsp3, Lane 4: pcDNA5/FRT/TO/HA-MERS-nsp3, Lane 5 pcDNA5/FRT/TO/HA-SARSnsp3 Mock: No transfection. Actin was used as loading control.
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Figure 3.5. Tet-inducible expression of WT and delPLP mutant of SARS-CoV
nsp3 in HeLa-Fit derived cells.
HeLa-Fit-SARS-nsp3 and HeLa-Fit-SARS-nsp3-delPLP stable cells were grown for 48 h
in the absence (Tet-) (lanes 1) or presence (Tet+) ( lanes 2) of 2 µg/ml of Tet. Using
mouse anti HA mAb (12CA5 hybridoma culture supernatant) inducible expression of
SARS-nsp3 and SARS-nsp3-delPLP was analyzed by western blotting.
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system developed by Gossen and Bujard (225) has been widely used to control inducible
expression of proteins in cultured mammalian cells. Tet inducible systems are divided
into two classes, the Tet-On system in which gene expression is induced in the presence
of tetracycline, and the Tet-Off system where expression of a gene is turned off by Tet
(234). Although there are two variants of the Tet based system, we decided to use the
Tet-on system due to its advantage of not exposing the cells to Tet for prolonged periods
of time under non-inducing conditions. While possessing many unique attributes, the Tetregulated gene expression system has undergone many modifications to tighten the
control of gene expression.
The Flp-In T-Rex system (Invitrogen) uses a genomic FRT site for integration of
a gene-of-interest (GOI) by FLP recombinase and is based on the Tet-repressor (TetR)
that inhibits, via two tetracycline operator (tetO) sequences immediately downstream of
the CMV promoter, expression of the GOI (229). The incorporation of FLP recombinasemediated integration into a pre-integrated FRT site is a useful addition to the Tetregulated expression system. It is suggested that this will routinely generate highly
reproducible stable transgenic cell lines in which protein expression is induced and
comparable across a population of cells. To achieve highly reproducible results, sitespecific integration of one single gene copy is important. Therefore, to elucidate the
functional role of various CoV-nsp3 proteins on the antagonism of the host antiviral
innate immune responses, I chose the well-characterized Flp-In-T-Rex expression system
to generate stable cell lines that express, in a Tet-regulated fashion, the full-length nsp3
protein of HCoVs OC43, NL63, MERS-CoV and SARS-CoV, respectively.
In the present study, the full-length cDNA of nsp3 from SARS-CoV, MERS-CoV,
HCoV-OC43, and HCoV-NL63 was cloned into a mammalian expression vector, and
positive clones were identified by restriction enzyme digestion of mini-preps Figure
3.1A-3.1E. Subsequently, Western-blot analysis confirmed that the recombinant
plasmids enabled expression of the full-length OC43-nsp3, NL63-nsp3, MERS-nsp3, and
SARS-nsp3 proteins, in transient transfection experiments Figure 3.2A-3.2E. The FlpIn-T-Rex stable cell lines were utilized to ensure comparable expression amongst each
CoV-nsp3 Tet inducible cell line, thus allowing the investigation of CoV-nsp3 effects in
physiologically relevant conditions. However, my findings suggest that there are
considerable variations between stable cells expressing different CoV-nsp3 proteins (data
not shown). In an attempt to understand the underlying reason, I assayed transient
expression of all four CoV-nsp3 proteins from the CoV-nsp3 expression constructs used
to generate the stable expressing cells Figure 3.4. It is possible that the mRNA levels of
each CoV-nsp3 proteins are different, or that the codons of different CoV nsp3s differ in
their efficiency for expression in human cells. While various approaches were taken to
enhance the diminished expression of MERS-CoV-, HCoV-OC43-, and HCoV-NL63nsp3 proteins, I show in this study that comparable expression of nsp3 among all four
CoV-nsp3 stable cell lines could not be achieved (data not shown).
A good way to study the function of a viral protein is to see what happens in the
host cell when the protein is present. For this, using a cell-culture system that stably
expresses the viral protein is advantageous. However, research conducted while
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characterizing CoV-nsp3 stable expressing cell lines demonstrates that the generation of
stable Tet-inducible cell culture systems that express large viral proteins in mammalian
cells can be very complex. Ultimately, with these kind of studies, many biological aspects
must be considered in the development of these cell-culture systems. One may argue that
the amount of mRNA transcribed does not necessarily equal the amount of protein
produced. However, there are instances in which variations in mRNA levels strongly
correlate with change in protein levels. It is possible that the expression of CoV-nsp3
genes is tightly controlled at the levels upstream of translation. Therefore, it would be
important for this project to measure each CoV-nsp3 gene product. Quantifying the level
of mRNA transcripts will indicate at what magnitude each CoV-nsp3 gene is transcribed.
To visualize variances in the abundance of mRNA transcripts produced by the different
CoV-nsp3 stable cells or at different times, I could use the RT-qPCR method. In this
technique, reverse transcription is followed by quantitative PCR. This will be an
important way to determine if there are differences in the transcriptional regulation of the
CoV-nsp3 proteins, thus causing differences in CoV-nsp3 protein production.
Interestingly, Western blot analysis demonstrates that SARS-CoV-nsp3 protein is
expressed robustly in either stable Figure 3.3D or transient Figure 3.4 lane 5 expression
settings. This observation strongly suggests that the SARS-CoV codon is optimal for
expression in human cells. Notably, this is not a cell type-specific phenomenon, as 293Fit-SARS-nsp3 stable cells also demonstrated robust, inducible expression of SARSnsp3. With adjusting the codon usage within HCoV-OC43-, HCoV-NL63-, and MERSCoV- nsp3 genes to the codons most commonly used by human cells, expression of these
CoV nsp3s may be achieved (235). Several studies have demonstrated that codon
optimization can strongly enhance protein expression from several of human
immunodeficiency virus type-1 (HIV-1) genes in human cells (235-236). Even though
codon optimization suggests a primary effect on the translation of the protein, it has been
suggested that codon optimization could also lead to higher levels of mRNA
accumulation (237). Therefore, codon optimization is one approach that may be used to
increase CoV-nsp3 expression levels.
Although, comparable expression of different CoV-nsp3s was not achieved, the
generation of stable cell lines has many advantages over transient gene expression
systems, such as a more uniform gene expression within a cell population, the elimination
of the need for multiple transfections during experiments, and provision of a system for
long-term experiments (238). The Flp-In T-Rex system enables the targeted insertion of
exogenous GOI in a site-specific manner in all transfected cells, thus eliminating the
potential influence of random genomic insertion and ensuring homogenous levels of the
GOI expression, allowing for comparisons to be made. There has been much success in
utilizing this system to induce expression of mammalian proteins to investigate factors
that control cell proliferation and to reproducibly identify target genes of transcription
factors (239). Our laboratory previously used this system to demonstrate that TRIM56, an
IFN- and virus-inducible E3 ubiquitin ligase, is a positive regulator of the TLR3 antiviral
signaling pathway (223). More recently, we used this system to determine the molecular
basis of the versatility and specificity of TRIM56's antiviral activities against positivestrand RNA viruses (240). Moreover, using the Tet-Off version of the Tet-regulated
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expression system, work from this lab first identified the PLpro of SARS-CoV as a potent
IFN antagonist, which disrupts IRF-3-dependent IFN induction by interacting with IRF-3,
and inhibiting its phosphorylation and nuclear translocation (186).
In future studies, to provide a more genetically homogenous and clonal
population, individual CoV-nsp3 clones allowing higher expression levels may be
selected through limiting dilution. Moreover, it may be useful to tag CoV-nsp3 with a
fluorescent marker (e.g., GFP) and sort high expressers by flow cytometry. In conclusion,
I have generated a tetracycline-inducible gene expression model system in HeLa cells
that stably express SARS-CoV-nsp3 Figure 3.3D. I have demonstrated that HeLa-FitScoV-nsp3 cells express SARS-CoV-nsp3 robustly and the expression is comparable to
that of a mutant nsp3 lacking the PLP domain in the HeLa-Fit-ScoV-nsp3-delPLP cell
line Figure 3.5. Such inducible cell lines can serve as a valuable in-vitro model system
for studying the function of SARS-CoV proteins, which will provide insight into SARS
pathogenesis.

44

CHAPTER 4. REGULATION OF IRF-3-DEPENDENT INNATE IMMUNE
SIGNALING PATHWAY BY THE PLPRO DOMAIN OF NONSTRUCTURAL
PROTEIN (NSP3) OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS)
CORONAVIRUS (COV)
Introduction
The innate immune response constitutes the first line of defense upon viral
infection. A hallmark of the host innate immune response to invading viral pathogens is
the rapid induction of type I IFNs (IFNα and IFNβ) (155). Type I IFNs are potent
antiviral cytokines that function in an autocrine/paracrine fashion to induce the
expression of hundreds of IFN-stimulated genes (ISGs) in the host early after virus
exposure, thereby establishing an antiviral state that inhibits viral replication and viral
spread (147,154-155). Because of these essential antiviral properties, type I IFNs are
considered master regulators of antiviral immunity. In addition to direct inhibition of
viral replication and spread, another level of IFN action is to shape the adaptive and
acquired immune responses. The induction of type I IFNs begins by cellular patternrecognition receptors (PRRs) detection of viral molecular signatures called pathogenassociated molecular patterns (PAMPs) (241). Toll-like receptors (TLRs) and retinoicacid-inducible gene I (RIG-I)-like receptors (RLRs) are two important classes of PRRs
that have been shown to be involved in the recognition of virus-specific components,
such as viral surface glycoproteins, intracellular viral proteins, and viral nucleic acids
(140, 146, 147, 241). Of these, double-stranded RNA (dsRNA) is a prominent viral
PAMP produced by many RNA viruses as viral replication intermediates, and dsRNA is
sensed by RIG-I, MDA5, and TLR3 to trigger IFNβ induction (147-150, 241).
Upon engaging viral dsRNAs, RIG-I, MDA5, and TLR3 recruit their cognate
adaptor proteins MAVS and TRIF respectively, triggering intracellular signaling
pathways converging on a common TRAF3 adapter complex, which then activates two
protein kinases TBK1 and IKKε. These kinases function to activate three distinct
families of transcription factors, including NF-ĸB, ATF2/c-Jun and IRF-3
(146,147,154,158). Assembly of these three transcription factors to the positive
regulatory domains (PRD) in the IFNβ promoter region induces transcription of the IFNβ
gene. Of these three transcription factors, IRF-3 is the main regulator in the initial
induction of IFNβ gene expression induced by viruses. IRF-3 is a constitutively
expressed protein that resides in an inactivated state in the cytosol. Upon virus infection,
activated TBK1 and IKKε directly phosphorylate serine 385 and 386 residues on the
carboxyl-terminal (c-terminal) region of IRF-3 (242). Furthermore, IRF-3 has been
shown to undergo virus-induced phosphorylation on a serine-threonine cluster in the Cterminal region, at amino acids (aa) 396 to 405 (220). Phosphorylated IRF-3 forms
homo-dimers, translocates into the nucleus and binds to its target DNA sequence on the
IFNβ promoter, resulting in the induction of IFN-β gene expression (156-158).
Consequently, for every host defense, there is a viral offense, and during coevolution
with their hosts, viruses have evolved and adapted strategies to exploit and modulate the
cellular IFN responses by encoding viral factors that disrupt host innate immune
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signaling pathways. The interplay between a virus and its host early in infection largely
defines disease pathogenesis, thus defining the mechanisms by which viruses modulate
the host innate immune response, and may provide valuable knowledge that can facilitate
the development of vaccines and antiviral therapeutics.
SARS-CoV emerged from a zoonotic reservoir in late 2002 to cause the first
epidemic of the millennium. First identified in Guangdong Province, China, SARS-CoV
is the causative agent of the highly contagious viral respiratory disease known as Severe
Acute Respiratory Syndrome (SARS) (5). Over a small number of months, this novel
viral disease became a worldwide threat, spreading to more than two dozen countries
across 5 continents, infecting 8098 people of all ages, with the elderly more severely
affected. The World Health Organization (WHO) reported that of those 8098 people who
became ill, 774 died
(http://www.who.int/csr/sars/country/table2003_09_23/en/index.html), 68). In humans in
whom the outcome was fatal, SARS disease was associated with continued uncontrolled
viral replication and an aberrant inflammatory response in the lung, suggesting that
SARS-CoV evades and/or modulates host innate antiviral immune responses (68). The
SARS epidemic has sparked a keen interest among the scientific community to focus its
attention on the capacity of coronaviruses to counteract or evade the host innate immune
system and on the need to develop preventive strategies to protect against SARS-CoV
should the virus re-emerge. In 2012, another highly pathogenic coronavirus emerged to
cause severe disease in humans, named MERS-CoV, which has a mortality rate of 38%
(24). To date, there are no FDA-approved antiviral therapeutics or vaccines for any of the
human coronaviruses. Although there have not been any reported SARS cases in humans
since 2004, the emergence of MERS-CoV nearly ten years later illustrates that highly
pathogenic coronaviruses will likely continue to emerge from zoonotic sources to cause
severe disease in the human population. Furthermore, such emergence highlights the need
for the discovery of antiviral drugs and/or vaccines against infections caused by
coronaviruses.
SARS-CoV genome is a large, nonsegmented, positive-stranded, 5’-capped, 3’polyadenylated RNA molecule that can function as messenger RNAs (mRNAs) (1).
Fourteen functional open-reading frames have been identified in the genome of SARSCoV (4,116). As with all coronaviruses, genomic RNA is released in the cell cytoplasm
after infection and translated into two large replicase polyproteins, called pp1a and pp1ab
(1, 5, 118). The replicase polyproteins are autoproteolytically cleaved by two viral
cysteine proteases, the papain-like protease (PLpro) and a 3C-like protease (3CLpro), to
generate 16 nonstructural proteins (nsp 1 to 16). The nsps, also referred to as the
replicase proteins, function to assemble with host cell membranes to generate a complex
network of double membrane vesicles (DMV), essential for viral RNA replication (3,
118, 120-122). For these viruses, the PLpro is essential for processing the aminoterminal end of the replicase polyproteins at 3 junctions, through the recognition of
LXGG motif, releasing nsp1-nsp3 mature proteins from the viral polyprotein,
respectively (120, 133). Since they are critical for SARS-CoV replication, they are
attractive targets for antiviral treatments.
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The PLpro domain resides within nsp3, which is the largest replicase subunit.
Nsp3 is a multifunctional, multidomain protein; however, the function of many of the
domains identified within SARS-CoV nsp3 is not well known. Nevertheless, the
investigation of the papain-like protease of SARS-CoV has illustrated the multifunctionality of coronaviral PLPs. Several reports have demonstrated that the PLpro
domain of nsp3 functions not only as a viral protease, but also possesses deubiquitinating
(DUB) and deISGylating activities (135, 138-139, 199, 201). The host cell uses both Ub
and ISG15 as unique signaling components to promote the antiviral innate immune
responses during viral infection. The fact that SARS-CoV PLpro can cleave and disrupt
important host cell innate immune elements illustrates the multifunctional nature of this
protease and suggests that it is a major virulence factor.
SARS-CoV generally does not induce type I IFN in infected cells in culture,
which suggests that SARS-CoV evades or suppresses the induction of type I IFN (162).
We previously demonstrated that PLpro domain of SARS-CoV nsp3 is a potent IFN
antagonist, which acts to suppress IRF-3-dependent type I IFN induction by interacting
with IRF-3 and inhibiting its phosphorylation, dimerization, and nuclear translocation
(186). Furthermore, we showed that the inhibition of the IFN response was independent
of the protease activity. Although the mechanisms of actions are different, other groups
have demonstrated a similar phenomenon that SARS-CoV PLpro can inhibit IRF-3dependent type I IFN induction (194). Most of the in-vitro studies examining the
functional role of the PLpro domain have mainly used truncated nsp3 PLpro domain
constructs. On the contrary, Wathelet et al transiently expressed SARS-CoV full-length
nsp3 protein in HEK293T cells and demonstrated that nsp3 expression could inhibit
virus-induced type I IFN induction (191). However, the authors did not dissect the
antagonistic properties of nsp3 and determine what domain was responsible for this
ability. To our knowledge, it has not been shown whether expression of SARS-CoV
PLpro impacts IRF-3 signaling when stably expressed in the context of the full-length
nsp3 protein, which is the case in virus-infected cells.
The objective of this study was to investigate the effects of SARS-nsp3
expression on the IRF-3 innate immune signaling pathway. Examining the function of
PLpro on induction of the type I IFN responses to viruses, in the context of the full-length
nsp3 protein, is essential to the understanding of SARS pathogenesis. In this present
study, I provide evidence that SARS-nsp3 contributes to SARS-CoV antagonism of IRF3-dependent host innate immune responses and that this ability is dependent on the PLpro
domain.
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Results
Inducible Expression of SARS-CoV Nsp3 Inhibits IRF-3-Dependent Antiviral Gene
Responses.
To guard against virus infection, mammalian cells employ a complex antiviral
defense program characterized by the rapid induction of immediate early antiviral genes
such as (IFN-α/β), ISG15 and ISG56 (160). We have previously reported that the PLpro
domain inhibits the activation of the IFN-β promoter following engagement of TLR3 or
RIG-I pathways (186). As mentioned above, the PLpro domain is a catalytically active
domain within nsp3. Therefore, I investigated whether SARS-nsp3 behaves in a similar
fashion and can regulate the induction of IRF-3-dependent type I IFN responses. To
examine the effect of SARS-nsp3 in the antagonism of type I IFN responses, I used the
Flp-In-T-Rex expression system to generate HeLa cells that stably express SARS-nsp3,
in a tetracycline-regulated fashion named HeLa-Fit-ScoV-nsp3. The SARS-nsp3 protein
is tagged with a 2xHA-epitope at the N-terminus, to facilitate its detection. This system is
unique as it allows for the generation of stable, inducible cell lines using site-specific
recombination and integration mediated by Saccharomyces cerevisiae-derived Flp
recombinase (229), thus obliterating the sometimes difficult transient expression
dynamics, where the efficiency of transfection decreases with very large expression
plasmids. Furthermore, some cell lines may be refractory to transfection.
HeLa-Fit-ScoV-nsp3 cells in the absence or presence of Tet, to repress or induce
expression of SARS-nsp3, were cotransfected with a plasmid expressing the firefly
luciferase reporter gene under control of the human IFNβ promoter and a constitutively
expressed Renilla luciferase-encoding plasmid. The Renilla luciferase activity serves as
an internal control to normalize the transfection efficiency of the IFNβ reporter plasmid.
After induction of the IFN pathway by SeV infection, a known potent inducer of IRF-3dependent gene expression via RIG-I pathway, firefly luciferase activity was measured
and normalized relative to Renilla luciferase expression. As expected, the IFN-β
promoter is activated through TLR3 (data not shown) or RIG-I pathways (Figure 4.1);
however, in the presence of SARS-nsp3, activation of the virally induced IFNβ promoter
is significantly reduced Figure 4.1. SARS-nsp3 expression did not affect SeV infection,
since SeV protein expression detected shows comparable levels in Tet-induced and
uninduced HeLa-Fit-ScoV-nsp3 cells.These data suggest that SARS-nsp3 inhibits IRF-3dependent transcription of IFN-β. I therefore investigated the ability of SARS-nsp3 to
prevent the induction of an additional well-characterized IRF-3-dependent target gene,
ISG56, and determined if this ability is dependent on the PLpro domain.
Inverse PCR mutagenesis was employed to generate a SARS-nsp3 PLpro domain
deletion construct. Using the strategy that I implemented to generate the HeLa-Fit-ScoVnsp3 cell line, I created HeLa cells that stably express HA-SARS-nsp3-delPLpro, in a
tetracycline-regulated fashion designated HeLa-Fit-ScoV-nsp3-delPLpro. These cells
were used in combination with HeLa-Fit-ScoV-nsp3 cells to evaluate SARS-nsp3’s
inhibitory effects on virus-induced ISG56 expression and to dissect the PLpro domain’s
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Figure 4.1. Inducible expression of SARS-CoV nsp3 inhibits virus-dependent
activation of the IFNβ promoter.
Activation of IFNβ promotor, HeLa-Fit-ScoV-nsp3 cells were grown for 48 h in the
absence (-Tet) (blue bars) or presence (+Tet) (red bars) of 2ug/ml Tet treatment to repress
or de-repress HA-SARS-nsp3 expression (Performed in triplicates). Subsequently, cells
were co-transfected with pIFNβ-luc (80ng/well) and pRL-TK (20ng/well). Cells were
then mock infected or infected with 100 HAU of SeV for 16 hrs prior to cell lysis and
assayed for relative luciferase activity as a readout of IFN-β activity. The error bars
represent standard deviation.

49

role in the antagonism of IRF-3-dependent type I IFN responses in the context of the
full-length nsp3 protein. In the absence of tetracycline in the culture medium, both cell
lines exhibited no detectable exogenous protein expression Figure 4.2 (odd numbered
lanes).
However, upon the addition of tetracycline into the culture medium, both cell
lines demonstrated robust expression levels of HA-SARS-nsp3 and HA-SARS-nsp3delPLpro respectively Figure 4.2 (even- numbered lanes). This finding suggests that
expression of the wild-type (wt) and delPLpro mutant of SARS-nsp3 is tightly regulated
by tetracycline and that their expression levels are comparable. Consistent with data
obtained from the IFN-β promoter assay Figure 4.1, I found that inducible expression of
wt HA-SARS-nsp3 greatly inhibited the SeV induction of endogenous ISG56 expression,
but in the presence of HA-SARS-nsp3-delPLpro mutant, this ability is lost Figure 4.2.
To further verify my observations, I used Image J software to quantify ISG56
expression. The value of ISG56 expression is a measure of the relative intensity of each
band compared to the standard (control cells -Tet), having a relative density value of 100.
In the presence of HA-SARS-nsp3, ISG56 band intensity was decreased by 52%,
illustrating the profound inhibitory effect that HA-SARS-nsp3 has on IRF-3-dependent
gene expression Figure 4.2 (left panel). Interestingly, there is a slight increase in ISG56
band intensity in the presence of HA-SARS-nsp3-delPLpro Figure 4.2 (right panel),
suggesting that SARS-nsp3 PLpro domain plays a key role in SARS-CoV escape from
host innate immune responses. These findings demonstrate that SARS-nsp3 has the
ability to efficiently disrupt virus-induced expression of IRF-3-dependent antiviral genes
and that this ability is dependent on the PLpro domain.
SARS-CoV Nsp3 Does Not Inhibit the JAK/STAT1 Pathway
Our data show that HA-SARS-nsp3 can inhibit the induction of type I IFN
responses; therefore, I also examined whether HA-SARS-nsp3 could inhibit type I IFN
signaling downstream of the IFN receptors. The JAK/STAT pathway is a wellestablished IFN-dependent pathway that is triggered by the secretion of type I IFNs.
Activation of this pathway consists of the nuclear translocation and initiation of gene
transcription by STATs, which have been activated in response to JAK-mediated
phosphorylation (160). To determine the effects that HA-SARS-nsp3 has on IFN
signaling, I examined the IFN-induced phosphorylation of Stat1, a key molecule that is
indispensable for the JAK/STAT pathway activity. HeLa-Fit-ScoV-nsp3 cells in the
absence or presence of Tet, to repress or induce expression of HA-SARS-nsp3, were
treated with IFN-α for 1 hr. Treatment with IFN-α induced the phosphorylation of
STAT1; however, in the presence of HA-SARS-nsp3, pSTAT1 protein expression was
not inhibited Figure 4.3. These data suggest that SARS-nsp3 does not block IFNdependent signaling.
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Figure 4.2. SARS-nsp3 ability to inhibit virus-induced ISG56 expression is
dependent on the PLpro domain.
Immunoblot analysis of HA-SARS-nsp3, HA-SARS-nsp3-delPLP, Actin, and ISG56
expression in HeLa-Fit-ScoV-nsp3 and HeLa-Fit-ScoV-nsp3-delPLP cells that were
mock infected (lanes 1:2 and 5:6) or challenged with SeV (100HAU; lanes 3:4 and 7:8)
for 16 hrs in the absence ( -Tet, odd-numbered lanes) or presence (+Tet, even-numbered
lanes) of 2ug/mL of Tet treatment for HA-SARS-nsp3 and HA-SARS-nsp3-delPLP
inducible expression.
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Figure 4.3. Inducible expression of SARS-Nsp3 does not inhibit IFN-induced
Stat1 Phosphorylation.
Immunoblot analysis of HA-SARS-nsp3, Actin, and pStat1 expression in HeLa-FitScoV-nsp3 cells that were mock treated (lanes 1 and 2) or treated with IFNα (200 units;
lanes 3 and 4) for 1 hour and (lanes 5 and 6) for 2 hrs in the absence (odd-numbered
lanes) or presence (even-numbered lanes) of 2ug/mL of Tet treatment for HA-SARSnsp3 inducible expression.
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SARS-CoV Nsp3 Has the Ability to Compromise the TLR3 and RIG-I Stimulated
Antiviral Response.
Vesicular Stomatitis Virus (VSV) replication is known to be highly sensitive to
the antiviral action of type I IFNs; thus, it is a useful tool to assay for antiviral activities.
To investigate SARS-nsp3-mediated inhibition of type I IFN induction, I studied the
effects of HA-SARS-nsp3 expression on the establishment of an antiviral state induced
by TLR3 and RIG-I ligands. It is well known that the TLR3 signaling pathway can be
stimulated by a synthetic dsRNA analog, polyriboinosinic:polyribocytidylic acid (poly
I:C) (243). As with viral dsRNAs, engagement of TLR3 with poly (I-C) activates the
TRIF-dependent pathway, culminating in the induction of type I IFNs, proinflammatory
cytokines, and chemokines, mediated by NF-κB and IRF-3 activation (222). Therefore,
HeLa-Fit-ScoV-nsp3 cells were left uninduced or induced with Tet, to repress or turn on
expression of HA-SARS-nsp3. 48 hrs later cells were either mock treated or treated with
poly (I-C) in the culture medium, to confer an antiviral state. Afterwards, cells were
either mock infected or infected with an engineered firefly luciferase reporter-expressing,
recombinant strain of vesicular stomatitis virus (VSV-Luc). Infected cells express the
firefly luciferase reporter protein; thus, measurement of firefly luciferase activity is a
readout for VSV replication. In the absence or presence of Tet, VSV-Luc replicated to
similar efficiencies in mock-treated HeLa-Fit-ScoV-nsp3 cells, as determined by the
VSV-encoded luciferase activity Figure 4.4A. Stimulation by poly (I-C) in the media
produced an antiviral state in HeLa-Fit-ScoV-nsp3 cells in the absence of Tet, resulting in
a significant reduction of VSV-luc replication, when compared to unstimulated cells
Figure 4.4A. However, in the presence of Tet (HA-SARS-nsp3 expression induced), the
poly (I-C)-induced antiviral state was compromised Figure 4.4A, suggesting that SARSnsp3 impairs the poly (I-C)-established antiviral state via TLR3.
Using tranfection of a hepatitis C virus (HCV) RNA Replicon RNA, a RIG-I
ligand, I investigated the ability of SARS nsp3 to disrupt the RIG-I-mediated induction of
the antiviral state. Stimulation with the HCV RNA replicon induces an antiviral state in
HeLa-Fit-ScoV-nsp3 cells in the absence of Tet, resulting in a significant reduction of
VSV-luc replication, when compared to unstimulated cells Figure 4.4B. However, in the
presence of SARS-nsp3, the RIG-I-induced antiviral state is compromised, as
demonstrated by the significant increase in VSV replication when compared to control
cells Figure 4.4B. To further prove the PLpro domain is responsible for SARS-nsp3mediated IFN antagonistic ability, I examined if inducible expression of SARS nsp3delPLpro mutant had the ability to disrupt the poly (I-C)-induced antiviral state. While
wt SARS nsp3 maintains the ability to significantly compromise the poly (I-C)-induced
antiviral state; SARS nsp3-delPLpro lost such ability.
VSV contains a ribonucleoprotein (RNP) complex that consists of the viral
genome RNA enwrapped by the nucleoprotein (NP), which serves as a template for
mRNA transcription as well as genome replication (1). Thus, to further investigate
SARS-nsp3 inhibition of IFN induction, I tested the effects of SARS-nsp3 on VSV NP
expression. The VSV NP is expressed robustly in the absence or presence of SARS-nsp3
Figure 4.5 (lanes 3 and 7). However, upon stimulation with HCV RNA in the absence of
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Figure 4.4. Inducible expression of SARS-nsp3 compromises TLR3 and RIG-I
mediated antiviral state.
(A) Cells grown in the absence (-Tet) or presence (Tet+) of 2ug/ml of Tet treatment for
inducible HA-SARS-nsp3 expression were mock stimulated or stimulated with poly (I-C)
(25ug/mL), followed by infection with VSV-Luc (MOI=0.1). At 6-8 h post infection,
cells were lysed for firefly luciferase assay. (B) HeLa-Fit-ScoV-nsp3 cells grown in the
absence (-Tet) or presence (Tet+) of 2ug/ml of Tet treatment for inducible HA-SARSnsp3 expression were mock transfected or transfected with HCV replicon RNA
(2ug/mL), followed by infection with VSV-Luc (MOI=0.1). At 6-8 h post infection, cells
were lysed for firefly luciferase assay. (C) Cells grown in the absence (-Tet) or presence
(Tet+) of 2ug/ml of Tet treatment for inducible HA-SARS-nsp3 and HA-SARS-nsp3delPLP expression were mock stimulated or stimulated with poly (I-C) (25ug/mL),
followed by infection with VSV-Luc (MOI=0.1). At 6-8 h post infection, cells were lysed
for firefly luciferase assay.
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Figure 4.5. Inducible expression of SARS-nsp3 compromises RIG-I mediated
antiviral state.
Immunoblot analysis of VSV-NP and Actin expression in HeLa-Fit-ScoV-nsp3 cells.
Cells grown in the absence (-Tet) or presence (Tet+) of 2µg/ml of Tet treatment. Cells
were mock transfected or transfected with HCV replicon RNA (2µg/mL), followed by
infection with VSV-Luc (MOI=0.1). At 6-8 h post infection, cells were lysed for
immunoblot analysis.
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Tet, VSV NP expression is greatly diminished Figure 4.5 (lane 4), when compared to
unstimulated cells Figure 4.5 (lane 3), suggesting that a RIG-I-mediated antiviral state is
produced. In comparison, upon turning on HA-SARS-nsp3 expression, VSV NP
expression is increased Figure 4.5 (lane 8) when compared to control cells, suggesting
that SARS nsp3 interferes with RIG-I- stimulated antiviral responses, permitting an
increase in VSV replication. These findings further prove that SARS-nsp3 has the ability
to compromise the TLR3- and RIG I-mediated antiviral response, and that this ability is
mediated by the PLpro domain.
SARS-CoV Nsp3 Level of Blockade
IRF-3 plays a pivotal role in the transcriptional regulation of the IFN-β promoter
and subsequent ISG expression (220, 242). To further establish which step of the IRF-3
signaling pathway leading to IRF-3 activation is targeted by SARS-nsp3, I determined
the effect of HA-SARS-nsp3 on the expression of ISG56, following overexpression of
signaling proteins known to participate in RIG-I/MDA5 and TLR3 pathways upstream of
IRF-3. I found that HA-SARS-nsp3 strongly diminished the expression of ISG56 by
overexpression of TBK1 or IKKε Figure 4.6A. In contrast, SARS-nsp3 expression had
no effect on ISG56 expression in cells overexpressing the constitutively active, phosphomimetic IRF-3 mutant, IRF-3-5D Figure 4.6A. To confirm the observations presented
above, image J was used to quantify the intensity of ISG56 bands. The intensity values of
ISG56 bands for HeLa-Fit-ScoV-nsp3 cells in the absence of Tet were set to 100 Figure
4.6A (odd-numbered lanes), and the values for ISG56 bands in the presence of Tet are
shown relative to those in the absence of Tet Figure 4.6A (even-numbered lanes). In
HeLa-Fit-ScoV-nsp3 cells overexpressing the empty vector, ISG56 band intensity in the
presence of SARS-nsp3 is decreased by 97% as compared with –Tet cells (no detectable
nsp3 expression), thus demonstrating the ability of SARS-nsp3 to inhibit IRF-3dependent ISG56 expression.
Overexpression of the kinases should constitutively drive up IRF-3 activation and
subsequent ISG56 expression; however, in the presence of SARS-nsp3, ISG56 band
intensity is decreased by 67% and 82% respectively Figure 4.6A (lane 6 and 8). In
contrast, in HeLa-Fit-ScoV-nsp3 cells overexpressing IRF-3-5D, ISG56 band intensity
increased in the presence of SARS-nsp3 Figure 4.6A (lane 10), suggesting that at this
level SARS-nsp3’s ability to impair the host innate immune responses is lost. The ability
of SARS-nsp3 to inhibit TBK1- and IKKε-dependent responses indicates that SARSnsp3 acts downstreaml of these signaling molecules to prevent IRF-3 activation. In
contrast, SARS-nsp3 was unable to inhibit ISG56 expression by overexpression of IRF-35D, suggesting that SARS-nsp3 functions to prevent the activation of IRF-3, but is unable
to disrupt IRF-3 function once it is activated by phosphorylation. Therefore, I conclude
from these experiments that HA-SARS-nsp3 disrupts IRF-3-mediated signaling by acting
at a level that is downstream of the IRF-3 kinases and upstream of phosphorylated IRF-3.
The active site of SARS-CoV PLpro consists of a canonical Cys1651-His1812Asp1826 catalytic triad (136). Mutation of any of the three sites is known to abolish the
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Figure 4.6.

SARS-nsp3 level of blockade dependent on its protease activity.

A) Immunoblot analysis of HA-SARS-NSP3, and ISG56 expression in HeLa-Fit-ScoVnsp3 cells grown in the absence (-Tet odd-numbered lanes) or presence (Tet+ evennumbered lanes) of 2ug/ml f of Tet treatment for FLG-SARS-nsp3 expression cells that
were transiently transfected with various signaling molecules within the TLR3 and RIG1/MDA5 pathways above and below the level of IRF-3; SeV-infected cells (lane 3 and 4)
serve as a positive control of the SARS-nsp3 blockade of ISG expression. (B)
Immunoblot analysis of HA-SARS-nsp3, and pIRF3 expression in HeLa-Fit-ScoV-nsp3
and HeLa-Fit-ScoV-nsp3-C1651A cells grown in the absence (-Tet odd-numbered lanes)
or presence (Tet+ even-numbered lanes) of 2ug/ml f of Tet treatment for HA-SARS-nsp3
and HA-SARS-nsp3-C1651A expression cells that were mock infected (lanes 1:2 and
5:6) or infected with SeV (100HAU; lanes 3:4 and 7:8) for 16 hrs. (C) Activation of IFNβ
promotor, HeLa-Fit-ScoV-nsp3 and HeLa-Fit-ScoV-nsp3-C1651A cells were grown for
48 h in the absence (-Tet) (blue bars) or presence (+Tet) (red bars) of 2ug/ml Tet
treatment to repress or de-repress FLG-SARS-nsp3 or FLG-SARS-nsp3-C1651A
expression Subsequently, cells were co-transfected with pIFNβ-luc (80ng/well) and pRLTK (20ng/well). Cells were then mock infected or infected with 100 HAU of SeV for 16
hrs prior to cell lysis and assayed for relative luciferase activity as a readout of IFN-β
activity. The error bars represent standard deviation.
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protease activity of the PLpro (135). Next, I determined whether the inhibition of IRF-3
activation by SARS-nsp3 is dependent on its protease activity. I conducted western blot
analysis, determining the ability of SARS-nsp3 and a protease-deficient SARS nsp3
mutant (C1651A) to inhibit virus-induced IRF-3 phosphorylation. I found that when
SARS-nsp3 was expressed, virus-induced phosphorylated IRF3 was reduced; however, in
the presence of the catalytic mutant SARS-nsp3-C1651A, there was no observable
reduction in phosphorylated IRF-3 expression Figure 4.6B. Quantification of the band
intensity of pIRF3 further supported the results observed. In the presence of SARS-nsp3,
pIRF3 band intensity decreased significantly by 64% Figure 4.6B (lane 4), yet in the
presence of the SARS-nsp3 mutant lacking catalytical activity, pIRF3 band intensity was
increased by 22%. Furthermore, SARS-nsp3 catalytic mutant is unable to inhibit the
activation of the IFN-β promoter Figure 4.6C, suggesting that SARS-nsp3 may
proteolytically cleave cellular proteins in this pathway to interfere with IRF-3 activation,
thus inhibiting the expression of phosphorylated IRF-3. Alternatively, mutation of the
C1651 residue in SARS-nsp3 PLpro domain may alter the overall structure of the nsp3
protein or its de-ubiquitinating activity, in ways that disrupt the ability to inhibit IRF-3
activation.
SARS-Nsp3 Mechanism of Action
It is well established that the TLR3 and RIG-I signaling cascades that elicit IFN-β
gene induction converge at the
phosphorylation and activation of IRF-3 (158). We have previously shown that SARS
PLpro domain inhibits TLR3- and RIG-I-mediated IRF-3-dependent IFN-β induction by
inhibiting IRF-3 phosphorylation, dimerization, and nuclear translocation (186).
Additionally, we previously showed a physical interaction of the PLpro with IRF-3, in
coimmunoprecipitation assays (186). Later studies have also associated the ability of
CoV PLPs to inhibit type I IFN induction with their ability to antagonize STING, an
important scaffolding molecule required for the activation of IRF-3, and this ability is
mediated by catalytic-dependent and catalytic-independent activities (217-218). Despite
the advances in understanding the mechanism by which SARS-CoV PLpro inhibits IRF3-dependent signaling, evidence suggests that SARS PLpro interferes with the host innate
immune responses by acting at a level that is downstream of TBK1 and IKK and in
proximity to IRF-3. This evidence encouraged us to characterize potential mechanisms of
SARS-nsp3 inhibition on IRF-3-dependent type I IFN induction. RIOK3 has been
described as an essential novel adaptor protein required for the cytosolic nucleic-acidinduced type I IFN response (244). Furthermore, RIOK3 functions downstream of TBK1
and upstream of IRF-3 activation, making it a potential target of nsp3.
To determine if SARS-nsp3 interacts with RIOK3 to interfere with IRF-3
activation, HeLa-Fit-HA-ScoV-nsp3 cells repressed or induced for SARS-nsp3
expression were transfected with a Flag-tagged RIOK3 construct. After 48 hours of
transfection, the protein complexes were extracted and subjected to immunoprecipitation
analysis. Cell lysates were assayed for both HA-tagged SARS-nsp3 and Flag-tagged
RIOK3, and both proteins were found to be expressed robustly Figure 4.7B. Co-IP
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Figure 4.7.

SARS-nsp3 does not associate with RIOK3.

(A) Cell lysates were subjected to immunoprecipitation (IP) with a mouse anti-HA and
anti-FLG antibody, followed by immunoblot analysis of HA-SARS-nsp3, and RIOK3FLG. Data shown are representative of two independently conducted experiments. (B)
HeLa-Fit-ScoV-nsp3 cells grown in the absence (-Tet odd-numbered lanes) or presence
(Tet+ even-numbered lanes) of 2ug/ml f of Tet treatment for HA-SARS-NSP3 expression
were transiently transfected with RIOK3-FLG plasmid for 48 hrs. Expression of HASARS-nsp3 and RIOK3 proteins in cell lysates was determined by immunoblot analysis.
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experiments using anti-Flag or anti-HA antibodies revealed that SARS-nsp3 does not
form a complex with RIOK3 Figure 4.7A. It has been reported that the DEAD-box
helicase DDX3 is also a crucial component in the TBK1/IKK𝜀-mediated activation of
IRFs and ultimately the induction of type I IFNs (245-247). Most importantly, DDX3 is
an important target for viruses to inhibit the induction of the antiviral innate response. For
example, Hepatitis B virus polymerase functions to inhibit PRR-induced type I IFN
induction by disrupting DDX3 and TBK1/IKKe complex (248). Likewise, DDX3 was
identified as a host target of VACV protein, K7, which can inhibit SeV-induced IFN-β
gene induction by inhibiting TBK1/IKKε-mediated IRF-3 activation (246). As with
RIOK3, although cell lysates revealed robust expression of endogenous DDX3, following
Co-IP experiments, no interaction was observed between HA-SARS-nsp3 and DDX3
(data not shown).
Discussion
The type I IFN (IFN-α/β) response is a crucial early antiviral defense mechanism
utilized by the host to combat invading viral pathogens. Type I IFNs function to establish
an antiviral state within infected and neighboring cells. IFN-β and -α1 gene expression is
mediated by the transcription factors IRF-3, NF-κB, and AP-1. Once translated and
secreted, IFN-β and -α1 bind to their cognate cell surface receptors in an autocrine and
paracrine fashion. This induces the JAK/STAT signaling pathway, which induces an
extensive range of interferon-stimulated genes (159,242-243). IRF-3 is also an essential
regulator of a subset of pro-inflammatory genes such as RANTES and CXCL10, and can
directly mediate the transcription of certain ISGs with ISRE sites including ISG15 and
ISG56 (156). Viruses must battle these immune responses to propagate successfully; as a
result, many viruses encode proteins that interfere with the initial induction of type I
IFNs, blocking JAK/STAT signaling or inhibiting the antiviral state at a later step.
The initial observation that SARS-CoV induces a poor IFN response led to the
assumption that the genome encodes antagonists of the IFN system. SARS-CoV has
created a number of strategies to inhibit type I IFN production. We have shown
previously that the PLpro domain contained within nsp3 is a potent IFN antagonist (186).
The PLpro domain was shown to inhibit IFN-β by blocking IRF-3 phosphorylation,
dimerization and nuclear translocation (186). Subsequent studies have also shown that
the PLpro domain blocks IRF-3-mediated IFN induction by diverse mechanisms (194).
However, the PLpro domain is contained within nsp3, a 213 kDa membrane-associated
replicase product. To understand fully the pathogenesis of SARS-CoV infection, studies
are needed to elucidate the mechanisms by which SARS-nsp3 interacts with its host and
subverts the host antiviral response. A detailed understanding of this interaction in the
context of the full-length nsp3 protein may yield important information that informs
development of effective antiviral therapeutics that can be used to attenuate highly
pathogenic coronaviruses’ replication and pathogenesis.
In the present study, I demonstrate that expression of SARS CoV full-length nsp3
protein can inhibit IRF-3-mediated antiviral defenses. In particular, inducible expression
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of nsp3 was shown to block the activation of virus-induced IFN-β promoter Figure 4.1
and ISG56 expression Figure 4.2A. SARS-CoV replication requires the proteolytic
processing of SARS-CoV replicase polyprotein into individual nsp proteins by two
virally encoded cysteine proteases, 3CLpro and the PLpro. Using an autoproteolytic
mechanism, the PLpro is responsible for the proteolytic cleavage of the amino terminal
end of the viral polyprotein, resulting in the release of nsp1, nsp2, and nsp3 (120, 134).
SARS-CoV proteolytic process requires an active site containing a classical catalytic
triad composed of amino acids Cys1651, His1812, and D1826 (120, 134). Interestingly, I
observed that the SARS-nsp3 C1651A protease mutant completely lost the ability to
block expression of pIRF3, suggesting that this residue is indispensable for SARS-nsp3mediated inhibition of IRF-3 activation Figure 4.6B. It is possible that this specific
mutation of the catalytic site may alter the conformation of the protein, thus affecting the
substrate binding event that drives the cysteine protease catalytic mechanism.
Although the evidence presented above suggests a protease-dependent mechanism
for type I IFN antagonism, it is important to consider that the DUB/delSGylation activity
of SARS nsp3 PLpro domain which may contribute to regulation of innate immunity is
dependent on the same active site. Therefore, I cannot exclude the possibility that SARSnsp3 may use the DUB/delSGylation activity to inhibit IRF-3 activation. Furthermore, it
is also possible that the C1651A mutation may alter the overall folding of the nsp3
protein, disrupting the interaction of nsp3 with potential signaling proteins in the IRF-3
activation pathway it targets, including iRF-3 itself. Thus, to better understand the role, if
any, of the catalytic activity in facilitating SARS-nsp3 PLpro inhibition of IRF-3
activation, it is essential to examine additional mutations in the PLpro domain, such as
the other two catalytic sites, in the context of the full-length SARS-nsp3 protein.
Nonetheless, we demonstrated that the ability of SARS-CoV nsp3 to antagonize IRF-3mediated gene expression is dependent on the PLpro domain Figure 4.2.
Activation of the type I IFN system results in the stimulation of a signal
transduction cascade that induces hundreds of ISGs, producing an antiviral state in host
cells and stimulates the adaptive immune responses (249). VSV is highly sensitive to
IFNs, and the presence of type I IFNs blocks VSV replication, as seen when stimulated
with TLR3 and RIG-I ligands to induce an antiviral state; however, this effect was
partially reversed by expression of SARS-nsp3 Figure 4.4A and Figure 4.4B. In
contrast, SARS-nsp3-delPLpro mutant lost the ability to compromise the establishment of
an antiviral state Figure 4.4C, demonstrating that SARS-nsp3 functions as a negative
regulator of TLR3- and RIG-I-mediated induction of the antiviral state, which is
dependent on the PLpro domain, in a biological assay system. Interestingly, our previous
results and data published by others have shown that the PLpro domain has the capacity
to inhibit IRF-3-dependent gene expression by blocking IRF-3 activation (186,194,
217,218). Here, I show that SARS-nsp3 inhibitory effect was bypassed by the expression
of a phospho-mimetic IRF-3 5D, a constitutively active form of IRF-3, indicating that
nsp3 interferes with IRF-3-mediated signaling in the vicinity of IRF-3, prior to its
activation Figure 4.6A. Most recently, Chen et al indicated that SARS-CoV PLpro
negatively regulates IRF-3- dependent antiviral innate immune responses by targeting the
IRF-3 scaffolding protein STING (217). In contrast to our observations and those of
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others, Matthews et al observed that SARS-CoV PLpro can inhibit IRF-3 signaling at a
step after IRF-3 activation, suggesting another antagonistic strategy of PLpro (250). It is
unclear why this effect was not observed by us and other research groups.
The PLpro domain may employ multiple mechanisms to inhibit IRF-3 signaling;
however, the detailed mechanism by which nsp3 inhibits IRF-3 activation has not been
described. In search for SARS-nsp3 interacting molecules, I identified two potential
cellular targets that function downstream of TBK1/IKKε and in the proximity of IRF-3.
It is well established that DDX3 is a component of the antiviral innate immune signaling
pathway leading to type I IFN induction. DDX3 contributes to the upregulation of type I
IFNs induction through the formation of a complex with IKKε or TBK1 (245-247). IKKε
phosphorylation of DDX3 is required for the recruitment of IRF-3 into the complex
(245). Interestingly, similar to STING, DDX3 functions as a bridging adaptor linking
IKK-related kinases to IRF-3. A recent study identified RIOK3 as a novel adaptor protein
that is crucial for IRF-3-mediated antiviral defenses (244). This study demonstrated that
RIOK3 functions downstream of TBK1 and upstream of IRF-3 activation. Furthermore,
RIOK3 physically formed a complex with both IRF-3 and TBK1 and is required for the
interaction between TBK1 and IRF-3 (244). However, upon our investigation, I found
that SARS-nsp3 does not interact with RIOK3 Figure 4.7A or DDX3 (data not shown).
It is possible that the experimental conditions used above do not promote SARS-nsp3
interaction with DDX3 or RIOK3, or that such interactions may be transient and weak.
Thus, it is important to further determine the potential interaction of SARS-nsp3 with
DDX3 and/or RIOK3, and search for other potential targets of SARS-nsp3. While the
mechanism of action of nsp3 was undefined in this study, future experiments are
underway to elucidate the precise mechanism by which SARS-nsp3 inhibits IRF-3dependent antiviral innate immune responses.
In conclusion, our investigations have demonstrated that SARS-nsp3 protein is a
bona-fide interferon antagonist, which acts through PLpro-mediated suppression of IRF-3
activation. SARS-CoV encodes many antagonists of the host innate immune response,
including open reading frame 6 (ORF6) protein, nucleocapsid, ORF3b, NSP1, NSP3, and
the PLpro domain (113, 114,186,191,192,194). Many of these IFN antagonists have
evolved different strategies to counteract the IFN system by inhibiting IFN synthesis
and/or signaling. By rapidly inhibiting type I IFN gene induction, SARS-CoV is able to
suppress the immediate early antiviral innate immune response, resulting in the
successful establishment of infection. The existence of multiple IFN antagonists in the
SARS-CoV genome exemplifies the importance of understanding the biology of virus
and host interactions.
The multifaceted strategies circumventing the initial host innate immune response
evolved by SARS-CoV likely support the replication and spread of this virus in different
cell types and different species. Results from this study demonstrate that SARS-nsp3 is a
key player in this context, suggesting a critical role for this protein in pathogenesis and
disease outcome. This work provides further insight into SARS-CoV antagonism of the
host innate immune response in a biologically relevant setting. Characterization of
virulence factors responsible for negatively regulating the IFN response is an essential
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component in the development of vaccines and therapeutics aimed at disrupting this
critical aspect of viral pathogenesis. Future studies should be directed towards
identifying the precise mechanism of SARS-nsp3-PLpro-mediated suppression of IRF-3
activation.
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CHAPTER 5.

DISCUSSION

An In-vitro System for Comparative Studies of Human Coronavirus (CoV)
Nonstructural Protein 3 (Nsp3)
The replication of coronaviruses is a highly orchestrated and complex process. To
date, coronaviruses contain the largest known RNA genome. Comparable to many other
positive-sense, single-stranded RNA viruses, coronaviruses’ genomic replication and
transcription are mediated by a large replication complex that is attached to rearranged
intracellular host membranes (118). Specifically, coronaviruses induce membrane
rearrangements called double-membrane vesicles (DMVs), which function as a structure
for viral genome replication and perhaps offer protection from the host defenses (121122). The important role of coronavirus nsp3 in virus replication has been shown by
several earlier reports (123,124). Nsp3 has been shown to interact with numerous of other
viral nonstructural proteins involved in replication and transcription and, as such, may
serve as a scaffolding protein for the recruitment of these viral non-structural proteins to
the site of DMVs. Angelini et al demonstrated that the full-length and the C-terminaltruncated form of nsp3 have membrane disarranging and proliferation abilities.
Furthermore, working in concert, nsp3, nsp4, and nsp6 have the ability to induce DMVs
which are similar to those observed in SARS-CoV infected cells (123).
Most importantly, nsp3 houses the coronavirus-encoded papain-like protease
(PLP), which plays a pivotal role in viral polyprotein processing and replication. All
human coronaviruses, except SARS-CoV and MERS-CoV, encode two PLPs. When two
PLPs are encoded, it is the PLP2 that functions similarly to SARS-CoV PLpro. The
PLpro mediates cleavage of the replicase polyproteins 1a and 1ab at 3 specific sites,
generating 3 mature nonstructural proteins (nsp) (from nsp1–3) (3,120, 259). It is well
established that the PLpro domain plays a role in antagonism of the host innate immune
response. To date, the study of coronaviruses’ PLP domain has been largely based on
utilizing truncated nsp3 constructs that represent specific domains, yet the way that the
full-length nsp3 protein contributes to antagonizing the antiviral host response to enable
successful virus infection is not clearly understood. I attempted to address this demand by
generating stable cell lines that express, in a tetracycline-regulated fashion, the full-length
nsp3 protein of human coronaviruses OC43, NL63, MERS-CoV and SARS-CoV,
respectively. Studies in the full-length nsp3 protein context will lead to a greater
understanding of the complex organization of SARS CoV viral proteins encoding the
viral proteases, as well as provide insights to their functional relationships.
In order to study the functional role of coronaviral nsp3 in regulation of the host
innate immune response, I desired to produce stable cell lines that permits the integration
of the full-length nsp3 expression construct into the host cell chromosome, cells that
could be used over many experiments, and with expression that is consistent and
comparable between experiments. Therefore, I utilized the Flp-In T-Rex-system to create
stable cell lines expressing coronaviral full-length nsp3 proteins in a tetracyclineregulated manner Figure 3.3A-E. This system is a very useful tool for functional studies
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because it allows for site-specific integration and stable expression of a gene of interest
(GOI), providing single-copy isogenic cell lines. Thus, integration should occur into the
same genomic locus in every clone. As a result, all clones should be identical
(Invitrogen). Furthermore, Flp-In expression involves introduction of an Flp
Recombination Target (FRT) site into the genome of the mammalian cell line of choice.
Thus, integration is site-specific, occurring at the FRT site (229). Single-copy sitespecific integration should eliminate the integration of multiple copies of integrants and
random sites of integration into the genome of the host cell. Thus, this system provides
comparable protein-expression levels within the same batch of cells. In addition, utilizing
one of the strongest mammalian promoters and regulatory elements from the tetracyclineresistance operon for transcription of the GOI should permit highly inducible expression
of the protein of interest.
Several lines of evidence suggest that this system would be useful for generating
stable cell lines in which inducible expression levels of the GOI are homogenous,
permitting the evaluation of the function of different coronaviral nsp3 proteins. However,
a particular observation demonstrated from IFA staining and Western blot analysis is
considerable variation in Tet-inducible expression levels among the full-length nsp3
protein of human coronaviruses OC43, NL63, MERS-CoV and SARS-CoV (data not
shown). Interestingly, this phenomenon was also observed via transient, ectopic
expression among the full-length nsp3 proteins Figure 3.4A, where the nsp3s would be
constitutively expressed from the strong CMV promoter. In contrast, upon the addition of
tetracycline into the culture medium, HeLa-Fit-ScoV-nsp3 cells demonstrated robust
expression of SARS-nsp3 Figure 3.5A, and this expression is comparable to HeLa-FitScoV-nsp3-delPLP cells expressing SARS-nsp3-delPLP Figure 3.5A. I postulate that the
variation in nsp3 expression levels among HeLa-Fit-OC43-nsp3, HeLa-Fit-NL63-nsp3,
and HeLa-Fit-MERS-nsp3 stable cells is not attributed to size of nsp3 because SARSCoV encodes the largest nsp3, yet HeLa-Fit-ScoV-nsp3 stable cells expressed SARSnsp3 most robustly.
It is important to note that, although belonging to the same family of viruses, there
are differences in the amino acid sequence of each coronaviral nsp3 gene (130). Thus it is
possible that HCoV-OC43, HCoV-NL63, and MERS-CoV codons are suboptimal for
expression in mammalian cells, as compared to that of SARS-CoV. It is possible that the
disproportionate levels of expression may be due to suboptimal efficiencies in the
transcriptional and/or translational regulation of specific coronaviral nsp3 proteins.
Further experiments are necessary to address the elements contributing to poor protein
expression of HCoV-OC43, HCoV-NL-63 and MERS-CoV-nsp3s in mammalian cells.
This is key to a comprehensive understanding of whether CoVs’ nsp3s may differ in their
effect on host innate immunity. Interestingly, the data provided in this body of work
suggest that SARS-CoV nsp3 sequence is optimal for expression in mammalian cells;
which may explain the rather large number of global SARS cases that spread rapidly in a
short period of time, highlighting the propensity of SARS-CoV to adapt readily to the
human host thereby allowing efficient human-to-human transmission. I have generated an
isogenic Tet-inducible gene-expression model system in HeLa cells that stably express
SARS-CoV-nsp3 and SARS-CoV-nsp3-delPLP Figure 3.5A. I have demonstrated that
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HeLa-Fit-ScoV-nsp3 cells express SARS-CoV nsp3 robustly and that expression is
comparable to HeLa-Fit-ScoV-nsp3-delPlpro cell line Figure 3.5A. Employing such
inducible cell lines can be useful for SARS-CoV-nsp3 functional studies, providing
insight into SARS pathogenesis.
SARS CoV Nsp3 Regulates Innate Immune Functions
Viruses are exceptionally diverse and have evolved to infect and cause disease in
almost all life forms, including humans. Needless to say, viruses can have a devastating
effect on public’s health. Prime examples are, the Spanish influenza (H1N1) pandemic in
1918, the transmission of the avian influenza virus (H5N1) to humans, and the sudden
emergence of two highly pathogenic coronaviruses that causes severe acute respiratory
syndrome (SARS) and Middle East respiratory syndrome (MERS). Thus, continued
studies of viral pathogens are necessary (42, 260, 261). Viral pathogenesis is the process
by which a virus causes disease in its host (1). A fundamental property of viruses is their
complete dependence on a living host for replication. Therefore, it must be noted that the
pathogenesis of a given virus is a combination of many multifaceted elements unique to a
specific virus and its individual host. This intimate relationship defines the nature of the
disease. A crucial component in understanding viral pathogenesis is defining the
fundamental mechanisms that determine the pathogenesis of infection between a host
with mild disease and the host that undergoes severe consequences. Thus, understanding
viral virulence genes and factors that contribute to disease will aid in the pursuit of
identifying specific targets for antiviral therapeutic interventions intended to prevent the
development of severe disease.
Host cells respond to invading viruses by initiating host innate immune responses
characterized by production type I interferons (IFN-α and β) and establishment of an
antiviral state (113,154-156, 241). The host innate immune response is a rapid first line of
defense mechanism against viral pathogens. SARS-CoV evades the innate immune
response through an intricate combination of virus-host interactions that disrupt
intracellular signaling pathways and weaken the antiviral actions of IFN. Viral regulation
of the host innate immune response disrupts the relationship between innate and adaptive
immunity, providing an environment conducive to SARS-CoV replication and spread.
One viral protein that is likely a significant virulence factor of SARS-CoV is the PLpro.
The PLpro domain has been shown to have interferon-antagonistic properties, which
offer SARS-CoV an advantage in its battle against the host innate immune defenses (186,
194, 217). This influence is mediated, at least in part by the ability of the PLpro to inhibit
the activation of IRF-3, a transcription factor required for the induction of IFN-β (159,
186, 194, 217, 220, 242).
Increasing evidence has shown that the PLpro possesses various IFN-antagonistic
properties (186, 194, 217, 258); however, little is known about the function of the fulllength nsp3 in disrupting IRF-3-dependent innate immunity. SARS-CoV PLpro is
contained within nsp3, a 213 kDa membrane multi-domain-associated replicase product
(3). In order to have a comprehensive understanding of the pathogenesis of SARS-CoV,
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studies clarifying the mechanisms by which SARS-nsp3 interacts with its host and
disrupts the host antiviral response are necessary. A detailed understanding of this
interaction in the context of the full-length nsp3 protein may result in biologically
relevant knowledge that potentially aid in the development of effective antiviral
therapeutics, which target highly pathogenic coronaviruses’ replication and mitigate
pathogenesis.
In this body of work, I tried to determine the molecular mechanism by which
SARS-nsp3 inhibits the IRF-3-dependent antiviral response. While the detailed
mechanism by which nsp3 inhibits IRF-3 activation still remains undefined, I have
provided evidence that the full-length nsp3 protein of SARS-CoV functions as a bonafide interferon antagonist, inhibiting IFN synthesis by acting at a level proximal to IRF3
Figure 4.6A. Furthermore, this ability is mediated by the PLpro domain and perhaps in
part, the catalytic activity Figure 4.6B. Future experiments that address the mechanism
of SARS-nsp3-mediated suppression of IRF-3 activation are essential to delineate the
exact role that nsp3 plays in SARS pathogenesis.
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